JP7433908B2 - Yarrow Fresh Plant Squeezed Juice Concentrate, Manufacture, and Use - Google Patents
Yarrow Fresh Plant Squeezed Juice Concentrate, Manufacture, and Use Download PDFInfo
- Publication number
- JP7433908B2 JP7433908B2 JP2019558768A JP2019558768A JP7433908B2 JP 7433908 B2 JP7433908 B2 JP 7433908B2 JP 2019558768 A JP2019558768 A JP 2019558768A JP 2019558768 A JP2019558768 A JP 2019558768A JP 7433908 B2 JP7433908 B2 JP 7433908B2
- Authority
- JP
- Japan
- Prior art keywords
- yarrow
- fresh plant
- skin
- weight
- juice concentrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000000073 Achillea millefolium Species 0.000 title claims description 137
- 235000007754 Achillea millefolium Nutrition 0.000 title claims description 136
- 241000196324 Embryophyta Species 0.000 title claims description 131
- 235000021579 juice concentrates Nutrition 0.000 title claims description 58
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 239000000203 mixture Substances 0.000 claims description 62
- 210000003491 skin Anatomy 0.000 claims description 60
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 52
- 239000003795 chemical substances by application Substances 0.000 claims description 46
- 239000002537 cosmetic Substances 0.000 claims description 39
- 239000012141 concentrate Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000003755 preservative agent Substances 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 21
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 19
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 19
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 13
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 239000003381 stabilizer Substances 0.000 claims description 12
- 229920002774 Maltodextrin Polymers 0.000 claims description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 11
- 238000001694 spray drying Methods 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 210000004927 skin cell Anatomy 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 9
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- UFCLZKMFXSILNL-PSEXTPKNSA-N Isochlorogenic acid b Chemical compound O([C@@H]1C[C@@](O)(C[C@H]([C@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-PSEXTPKNSA-N 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 4
- UFCLZKMFXSILNL-BKUKFAEQSA-N 3,4-di-O-caffeoylquinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O UFCLZKMFXSILNL-BKUKFAEQSA-N 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 229950009125 cynarine Drugs 0.000 claims description 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 4
- UFCLZKMFXSILNL-BBLPPJRLSA-N (-) 4,5-dicaffeoylquinic acid Natural products OC=1C=C(C=CC=1O)C=CC(=O)O[C@@H]1C[C@@](C[C@H]([C@H]1OC(C=CC1=CC(=C(C=C1)O)O)=O)O)(C(=O)O)O UFCLZKMFXSILNL-BBLPPJRLSA-N 0.000 claims description 3
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 claims description 3
- UFCLZKMFXSILNL-UHFFFAOYSA-N NSC 649410 Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC1C(O)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-UHFFFAOYSA-N 0.000 claims description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 3
- 229940031723 1,2-octanediol Drugs 0.000 claims description 2
- YDDUMTOHNYZQPO-BBLPPJRLSA-N 1,3-di-O-caffeoylquinic acid Natural products O[C@@H]1C[C@@](C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc1ccc(O)c(O)c1)C(O)=O YDDUMTOHNYZQPO-BBLPPJRLSA-N 0.000 claims description 2
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 claims description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- UFCLZKMFXSILNL-AALYGJCLSA-N 3,4-Dicaffeoylquinic acid Natural products O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@](O)(C(=O)O)C[C@@H]1O)/C=C/c1cc(O)c(O)cc1 UFCLZKMFXSILNL-AALYGJCLSA-N 0.000 claims 1
- MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 claims 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical group CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims 1
- 235000008504 concentrate Nutrition 0.000 description 32
- 239000000284 extract Substances 0.000 description 32
- -1 phenolic carboxylic acids Chemical class 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- 239000000126 substance Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 229920000642 polymer Polymers 0.000 description 22
- 239000000969 carrier Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- 239000000839 emulsion Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 238000004108 freeze drying Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 229920001577 copolymer Polymers 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 9
- 235000015872 dietary supplement Nutrition 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000002304 perfume Substances 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000001223 reverse osmosis Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 102100032442 Protein S100-A8 Human genes 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 7
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 101710156987 Protein S100-A8 Proteins 0.000 description 6
- 102000008063 Small Heat-Shock Proteins Human genes 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 235000010233 benzoic acid Nutrition 0.000 description 6
- 125000002091 cationic group Chemical group 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 108091052270 small heat shock protein (HSP20) family Proteins 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 5
- 102100037437 Beta-defensin 1 Human genes 0.000 description 5
- 229920000084 Gum arabic Polymers 0.000 description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 5
- 235000010489 acacia gum Nutrition 0.000 description 5
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000002085 irritant Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000722941 Achillea Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 4
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 4
- 239000004904 UV filter Substances 0.000 description 4
- CZNLTCTYLMYLHL-UHFFFAOYSA-N [6]-Paradol Chemical compound CCCCCCCC(=O)CCC1=CC=C(O)C(OC)=C1 CZNLTCTYLMYLHL-UHFFFAOYSA-N 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 229940074393 chlorogenic acid Drugs 0.000 description 4
- 235000001368 chlorogenic acid Nutrition 0.000 description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 4
- CRDAMVZIKSXKFV-YFVJMOTDSA-N (2-trans,6-trans)-farnesol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO CRDAMVZIKSXKFV-YFVJMOTDSA-N 0.000 description 3
- UFCLZKMFXSILNL-RVXRWRFUSA-N 4,5-di-O-caffeoylquinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-RVXRWRFUSA-N 0.000 description 3
- GYFFKZTYYAFCTR-JUHZACGLSA-N 4-O-trans-caffeoylquinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-JUHZACGLSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 108010052495 Calgranulin B Proteins 0.000 description 3
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 3
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 3
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010654 Melissa officinalis Nutrition 0.000 description 3
- 244000062730 Melissa officinalis Species 0.000 description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100032420 Protein S100-A9 Human genes 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 230000001166 anti-perspirative effect Effects 0.000 description 3
- 239000003213 antiperspirant Substances 0.000 description 3
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000008642 heat stress Effects 0.000 description 3
- 230000000544 hyperemic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000000865 liniment Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000003605 opacifier Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 2
- KRZBCHWVBQOTNZ-RDJMKVHDSA-N (3r,5r)-3,5-bis[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid Chemical compound O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 2
- WSRCOZWDQPJAQT-UHFFFAOYSA-N 18-methylicosanoic acid Chemical compound CCC(C)CCCCCCCCCCCCCCCCC(O)=O WSRCOZWDQPJAQT-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- TYBHZVUFOINFDV-UHFFFAOYSA-N 2-bromo-6-[(3-bromo-5-chloro-2-hydroxyphenyl)methyl]-4-chlorophenol Chemical compound OC1=C(Br)C=C(Cl)C=C1CC1=CC(Cl)=CC(Br)=C1O TYBHZVUFOINFDV-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 2
- GYFFKZTYYAFCTR-UHFFFAOYSA-N 5-O-(6'-O-galloyl)-beta-D-glucopyranosylgentisic acid Natural products OC1CC(O)(C(O)=O)CC(O)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 2
- 244000106483 Anogeissus latifolia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101710125314 Beta-defensin 1 Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- QNIFYGWWBZKEGO-JAIMSRQGSA-N C(\C=C\C1=CC(O)=C(O)C=C1)(=O)C1([C@@H](CC(C[C@H]1O)(C(=O)O)O)O)O Chemical group C(\C=C\C1=CC(O)=C(O)C=C1)(=O)C1([C@@H](CC(C[C@H]1O)(C(=O)O)O)O)O QNIFYGWWBZKEGO-JAIMSRQGSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 101100339887 Drosophila melanogaster Hsp27 gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 239000001922 Gum ghatti Substances 0.000 description 2
- 101150096895 HSPB1 gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000713322 Homo sapiens SAP30-binding protein Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 229940124091 Keratolytic Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004166 Lanolin Chemical class 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000015125 Sterculia urens Nutrition 0.000 description 2
- 240000001058 Sterculia urens Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 235000010237 calcium benzoate Nutrition 0.000 description 2
- 239000004301 calcium benzoate Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- GYFFKZTYYAFCTR-LMRQPLJMSA-N cryptochlorogenic acid Natural products O[C@H]1C[C@@](O)(C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GYFFKZTYYAFCTR-LMRQPLJMSA-N 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930002886 farnesol Natural products 0.000 description 2
- 229940043259 farnesol Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000019314 gum ghatti Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 235000010235 potassium benzoate Nutrition 0.000 description 2
- 239000004300 potassium benzoate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008263 repair mechanism Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 229940092258 rosemary extract Drugs 0.000 description 2
- 235000020748 rosemary extract Nutrition 0.000 description 2
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004334 sorbic acid Chemical class 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000005555 sulfoximide group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-UHFFFAOYSA-N (-) 3,5-dicaffeoyl-muco-quinic acid Natural products OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-UHFFFAOYSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-RDJMKVHDSA-M (-)-3,5-Dicaffeoyl quinic acid Natural products O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C([O-])=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-M 0.000 description 1
- YDDUMTOHNYZQPO-GCBRTHAASA-N (1r,3r,4s,5r)-1,3-bis[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-4,5-dihydroxycyclohexane-1-carboxylic acid Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-GCBRTHAASA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- YDDUMTOHNYZQPO-WXAIXHMISA-N 1,3-Bis-(3,4-dihydroxy-cinnamoyl)-chinasaeure Natural products O[C@H]1C[C@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-WXAIXHMISA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- OZIZFBLYKGBJPO-GCBRTHAASA-N 1,5-di-O-caffeoylquinic acid Natural products O[C@@H]1C[C@](C[C@@H](OC(=O)C=Cc2ccccc2)[C@H]1O)(OC(=O)C=Cc3ccccc3)C(=O)O OZIZFBLYKGBJPO-GCBRTHAASA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- USZDQUQLJBLEDN-UHFFFAOYSA-N 1-(1-tetradecoxypropan-2-yloxy)propan-2-yl propanoate Chemical compound CCCCCCCCCCCCCCOCC(C)OCC(C)OC(=O)CC USZDQUQLJBLEDN-UHFFFAOYSA-N 0.000 description 1
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical class C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 1
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 1
- UFCLZKMFXSILNL-GCBRTHAASA-N 102851-07-0 Natural products OC=1C=C(C=CC=1O)C=CC(=O)O[C@@H]1C[C@](C[C@H]([C@@H]1OC(C=CC1=CC(=C(C=C1)O)O)=O)O)(C(=O)O)O UFCLZKMFXSILNL-GCBRTHAASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UJTVNVOGXIDHEY-UHFFFAOYSA-N 2,3-dibromo-2,3-dimethylbutanedinitrile Chemical compound BrC(C(C)(C#N)Br)(C)C#N UJTVNVOGXIDHEY-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 description 1
- DHVLDKHFGIVEIP-UHFFFAOYSA-N 2-bromo-2-(bromomethyl)pentanedinitrile Chemical compound BrCC(Br)(C#N)CCC#N DHVLDKHFGIVEIP-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- KIUQCLHVRRCZLR-UHFFFAOYSA-N 2-methoxy-1h-pyridine-2-carboxylic acid Chemical compound COC1(C(O)=O)NC=CC=C1 KIUQCLHVRRCZLR-UHFFFAOYSA-N 0.000 description 1
- ZKYCLDTVJCJYIB-UHFFFAOYSA-N 2-methylidenedecanamide Chemical compound CCCCCCCCC(=C)C(N)=O ZKYCLDTVJCJYIB-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- YIEASZQRMGWKDX-UHFFFAOYSA-N 3,4-Di-O-caffeoylquinic acid Natural products OC1CC(O)(CC(OC(=O)C=Cc2ccc(O)c(O)c2)C1OC(=O)C=Cc3cccc(O)c3O)C(=O)O YIEASZQRMGWKDX-UHFFFAOYSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-WXAIXHMISA-N 3,5-di-O-caffeoylquinic acid Natural products O[C@@H]1[C@H](C[C@](O)(C[C@@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-WXAIXHMISA-N 0.000 description 1
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- GWXXFGWOWOJEEX-UHFFFAOYSA-N 4,4,4-trihydroxy-1-phenylbutan-1-one Chemical compound OC(CCC(=O)C1=CC=CC=C1)(O)O GWXXFGWOWOJEEX-UHFFFAOYSA-N 0.000 description 1
- GUQMDNQYMMRJPY-UHFFFAOYSA-N 4,4-dimethyl-1,3-oxazolidine Chemical compound CC1(C)COCN1 GUQMDNQYMMRJPY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- DSHJQVWTBAAJDN-SMKXDYDZSA-N 4-caffeoylquinic acid Natural products CO[C@@]1(C[C@@H](O)[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@H](O)C1)C(=O)O DSHJQVWTBAAJDN-SMKXDYDZSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- 229940073735 4-hydroxy acetophenone Drugs 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical class O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- FBNAWLJSQORPAX-UHFFFAOYSA-N 4-methyl-3-propan-2-ylphenol Chemical compound CC(C)C1=CC(O)=CC=C1C FBNAWLJSQORPAX-UHFFFAOYSA-N 0.000 description 1
- 229940046305 5-bromo-5-nitro-1,3-dioxane Drugs 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZRCMGIXRGFOXNT-UHFFFAOYSA-N 7a-ethyl-1,3,5,7-tetrahydro-[1,3]oxazolo[3,4-c][1,3]oxazole Chemical compound C1OCN2COCC21CC ZRCMGIXRGFOXNT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 235000004758 Bergkiefer Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 108010052500 Calgranulin A Proteins 0.000 description 1
- 241000190882 Capnocytophaga sputigena Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000911175 Citharexylum caudatum Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- LAAPRQODJPXAHC-UHFFFAOYSA-N Coniferyl benzoate Natural products C1=C(O)C(OC)=CC(C=CCOC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-UHFFFAOYSA-N 0.000 description 1
- GYFFKZTYYAFCTR-ZNEHSRBWSA-N Cryptochlorogensaeure Natural products O[C@@H]1C[C@@](O)(C[C@@H](O)[C@@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GYFFKZTYYAFCTR-ZNEHSRBWSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229920002245 Dextrose equivalent Polymers 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 108010033152 HSP90 Heat-Shock Proteins Proteins 0.000 description 1
- 102000007011 HSP90 Heat-Shock Proteins Human genes 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- BSIWGRBVPYYXSY-UHFFFAOYSA-N OC1=CC=C(C(=O)O)C=C1.C(C)[Na] Chemical compound OC1=CC=C(C(=O)O)C=C1.C(C)[Na] BSIWGRBVPYYXSY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 235000010450 Pino mugo Nutrition 0.000 description 1
- 241001136577 Pinus mugo Species 0.000 description 1
- 235000002914 Pinus uncinata Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000605385 Ruscus Species 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- ARCJQKUWGAZPFX-KBPBESRZSA-N S-trans-stilbene oxide Chemical compound C1([C@H]2[C@@H](O2)C=2C=CC=CC=2)=CC=CC=C1 ARCJQKUWGAZPFX-KBPBESRZSA-N 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 101150060340 S100a8 gene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100027224 Tumor protein p53-inducible nuclear protein 1 Human genes 0.000 description 1
- 108050003317 Tumor protein p53-inducible nuclear protein 1 Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000005083 Zinc sulfide Substances 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000001269 achillea millefolium l. oil Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229920006322 acrylamide copolymer Polymers 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002086 anti-sebum Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002519 antifouling agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- XVBRCOKDZVQYAY-UHFFFAOYSA-N bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- LAAPRQODJPXAHC-AATRIKPKSA-N coniferyl benzoate Chemical compound C1=C(O)C(OC)=CC(\C=C\COC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-AATRIKPKSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000020694 echinacea extract Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- PASCYLAFGHJSHW-UHFFFAOYSA-N ethyl 2-[(4-methoxyphenyl)methyl]-3-(methylamino)propanoate Chemical compound CCOC(=O)C(CNC)CC1=CC=C(OC)C=C1 PASCYLAFGHJSHW-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000012632 extractable Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000020721 horse chestnut extract Nutrition 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- MGIYRDNGCNKGJU-UHFFFAOYSA-N isothiazolinone Chemical compound O=C1C=CSN1 MGIYRDNGCNKGJU-UHFFFAOYSA-N 0.000 description 1
- 239000000177 juniperus communis l. berry Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940083980 lavender extract Drugs 0.000 description 1
- 235000020723 lavender extract Nutrition 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940048869 o-cymen-5-ol Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N ortho-phenyl-phenol Natural products OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940096825 phenylmercury Drugs 0.000 description 1
- DCNLOVYDMCVNRZ-UHFFFAOYSA-N phenylmercury(.) Chemical compound [Hg]C1=CC=CC=C1 DCNLOVYDMCVNRZ-UHFFFAOYSA-N 0.000 description 1
- PETXWIMJICIQTQ-UHFFFAOYSA-N phenylmethoxymethanol Chemical compound OCOCC1=CC=CC=C1 PETXWIMJICIQTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 description 1
- 229960002026 pyrithione Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- ARCJQKUWGAZPFX-UHFFFAOYSA-N stilbene oxide Chemical compound O1C(C=2C=CC=CC=2)C1C1=CC=CC=C1 ARCJQKUWGAZPFX-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- OEIXGLMQZVLOQX-UHFFFAOYSA-N trimethyl-[3-(prop-2-enoylamino)propyl]azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCNC(=O)C=C OEIXGLMQZVLOQX-UHFFFAOYSA-N 0.000 description 1
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- GAWWVVGZMLGEIW-GNNYBVKZSA-L zinc ricinoleate Chemical compound [Zn+2].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O.CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O GAWWVVGZMLGEIW-GNNYBVKZSA-L 0.000 description 1
- 229940100530 zinc ricinoleate Drugs 0.000 description 1
- 229910052984 zinc sulfide Inorganic materials 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/08—Concentrating or drying of juices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/08—Concentrating or drying of juices
- A23L2/082—Concentrating or drying of juices by membrane processes
- A23L2/085—Concentrating or drying of juices by membrane processes by osmosis, reverse osmosis, electrodialysis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/08—Concentrating or drying of juices
- A23L2/10—Concentrating or drying of juices by heating or contact with dry gases
- A23L2/102—Spray-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/08—Concentrating or drying of juices
- A23L2/12—Concentrating or drying of juices by freezing
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Water Supply & Treatment (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Emergency Medicine (AREA)
Description
本発明は、熱処理、保存剤または他の添加剤を用いる必要なしに長期保存することが可能なセイヨウノコギリソウ(Yarrow)フレッシュ植物圧搾汁濃縮物治療に関する。さらに、本発明は、こうしたセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を製造する穏やかな方法に関する。セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、化粧用組成物、医薬組成物、食品組成物または補助食品に使用される。
本発明はまた、セイヨウノコギリソウの使用の新たな態様にも関する。本発明は、皮膚細胞における熱ショックタンパク質および/または抗菌ペプチドの発現を刺激するためのセイヨウノコギリソウの使用を提供する。さらに、皮膚の熱耐性を増大するためのセイヨウノコギリソウの使用が記載される。
The present invention relates to a Yarrow fresh plant juice concentrate treatment that can be stored for long periods of time without the need for heat treatment, preservatives or other additives. Furthermore, the present invention relates to a gentle method of producing such a Yarrow fresh plant press concentrate. Yarrow fresh plant juice concentrate is used in cosmetic compositions, pharmaceutical compositions, food compositions or food supplements.
The invention also relates to new aspects of the use of Yarrow. The present invention provides the use of Yarrow to stimulate the expression of heat shock proteins and/or antimicrobial peptides in skin cells. Furthermore, the use of yarrow to increase the heat tolerance of the skin is described.
セイヨウノコギリソウ(Achillea millefollium)は、伝統的な薬用植物である。典型的な成分には、例えば、精油、セスキテルペン、例えばフラボノイドなどのフェノール化合物、フェノールカルボン酸、およびベタインが含まれる。フェノールカルボン酸の例には、クロロゲン酸および種々のジカフェオイルキナ酸が含まれる。
セイヨウノコギリソウは、抽出物の形態で使用される。液状抽出物の製造のために、例えば、フレッシュな(乾燥されていない)植物が使用され、すなわち、一般に出発植物材料は製造区域の近くで培養または採取されなければならない。成熟した植物が収穫され、かつ腐敗および微生物汚染を予防するために、タイミングよく(通常、1日以内に)圧搾されかつ瓶詰めされなければならない。
この方法で得られたセイヨウノコギリソウ圧搾汁は、例えば、膨満感および食欲不振を含む、消化管における軽度の痙攣性不快感に対して使用され得る。セイヨウノコギリソウはまた、その創傷治癒における好ましい特性により、スキンクリームにも使用される。
Achillea millefolium is a traditional medicinal plant. Typical ingredients include, for example, essential oils, sesquiterpenes, phenolic compounds such as flavonoids, phenolic carboxylic acids, and betaines. Examples of phenolic carboxylic acids include chlorogenic acid and various dicaffeoylquinic acids.
Yarrow is used in the form of an extract. For the production of liquid extracts, for example, fresh (not dried) plants are used, ie the starting plant material generally has to be cultivated or harvested close to the production area. Mature plants must be harvested and pressed and bottled in a timely manner (usually within one day) to prevent spoilage and microbial contamination.
Yarrow juice obtained in this way can be used for mild spasmodic discomfort in the gastrointestinal tract, including, for example, bloating and loss of appetite. Yarrow is also used in skin creams due to its favorable properties in wound healing.
セイヨウノコギリソウ抽出物は、局所適用のための化粧品において、すでに広範に使用されている。これらは乾燥薬剤から製造される抽出物である。乾燥は、季節ごとの収穫期に対する時間的非依存性および腐敗可能性からの保護を提供する。乾燥植物材料は保存することができ、より容易にかつより費用効率よく運搬することができる。しかし、植物材料を乾燥する間および抽出物の製造(抽出、必要に応じて、熱供給および通常はそれに続いての濃縮のための加熱下での抽出剤の留去)の間に、植物の構成要素のスペクトルに部分的な変化が起こる。
セイヨウノコギリソウフレッシュ植物圧搾汁の工業的製造は、圧搾する植物または植物部位を収穫し、清浄化し、切り刻み、植物酵素の不活性化および植物材料の分解のための水蒸気処理、加圧下での圧搾、ろ過または遠心分離、滅菌のための超高温短時間加熱および無菌充填により、一般的に行われる(Deutsche Apothekerzeitung 2011, p. 93 ff.)。こうしたフレッシュ植物圧搾汁は、通常、2~6質量%の乾燥抽出物または乾燥汁を含む。これは、高温が短時間しか使用されない、穏やかなプロセスである。さらに、比較的少ない作業ステップしか必要としない。これは、抗酸化剤などの敏感で生物学的に活性な成分を確実に保護するためである。
Yarrow extract is already widely used in cosmetics for topical application. These are extracts made from dry drugs. Drying provides time independence from seasonal harvest periods and protection from possible spoilage. Dried plant material can be stored and transported more easily and cost-effectively. However, during the drying of the plant material and during the production of the extract (extraction, if necessary heat supply and distillation of the extractant under heat, usually followed by concentration), the A local change occurs in the spectrum of the constituents.
The industrial production of fresh yarrow plant juice involves harvesting the plant or plant parts to be pressed, cleaning and chopping, steam treatment for inactivation of plant enzymes and decomposition of the plant material, pressing under pressure, This is commonly done by filtration or centrifugation, short-term heating at very high temperatures for sterilization, and aseptic filling (Deutsche Apothekerzeitung 2011, p. 93 ff.). Such fresh plant juices usually contain 2-6% by weight of dry extract or juice. This is a mild process in which high temperatures are used for only short periods of time. Furthermore, relatively few work steps are required. This is to ensure the protection of sensitive and biologically active ingredients such as antioxidants.
欠点は、得られたフレッシュ植物圧搾汁は、密閉容器においてのみ保存ができ、そうでない場合、微生物汚染のリスクがあることである。結果として、フレッシュ植物圧搾汁は、特に最終消費者にとって、取扱いが難しい。これは、完全に使い切ることが必要であるかまたは腐敗から保護するためにフレッシュ植物圧搾汁への望ましくない保存剤の添加が必要であるという事実によるものである。 The disadvantage is that the fresh plant juice obtained can only be stored in closed containers, otherwise there is a risk of microbial contamination. As a result, fresh plant juice is difficult to handle, especially for the end consumer. This is due to the fact that it is necessary to use it up completely or to add undesirable preservatives to the fresh plant juice in order to protect it from spoilage.
したがって、本発明の一目的は、長期保存が可能なセイヨウノコギリソウ抽出物およびそうした抽出物の製造方法を提供することである。さらなる一目的は、保存剤または他の添加剤を使用することなく保存できるセイヨウノコギリソウ抽出物を提供することである。成分のプロファイルは、製造プロセスまたは保存によって影響を受けるべきではない。さらに、技術水準において公知の適用可能性と比較して有利な追加の応用を提供する水性セイヨウノコギリソウ抽出物が提供されるべきである。技術水準は、熱ショックタンパク質および/または皮膚AMPを刺激する活性物質を記載している。それにもかかわらず、新たな天然由来の忍容性良好な、化粧用処方に導入が容易なHSPおよび/またはAMP刺激剤に対するニーズが存在する。
したがって、本発明は、100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物に対して、
10~100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、
0~90質量%の水、および
0~90質量%の担体
を含むかまたはからなる、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物に関する。
Therefore, one object of the present invention is to provide a yarrow extract capable of long-term storage and a method for producing such an extract. A further object is to provide a yarrow extract that can be stored without the use of preservatives or other additives. The ingredient profile should not be affected by the manufacturing process or storage. Furthermore, an aqueous yarrow extract should be provided which offers advantageous additional applications compared to the application possibilities known in the state of the art. The state of the art describes active substances that stimulate heat shock proteins and/or skin AMPs. Nevertheless, there is a need for new naturally derived, well-tolerated HSP and/or AMP stimulants that are easy to incorporate into cosmetic formulations.
Therefore, the present invention provides for 100% by weight of Yarrow fresh plant pressed juice concentrate:
10 to 100% by mass of yarrow fresh plant pressed juice dry residue,
A fresh plant juice concentrate of Yarrow comprising or consisting of 0 to 90% by weight of water and 0 to 90% by weight of a carrier.
さらに、本発明は、
セイヨウノコギリソウフレッシュ植物圧搾汁を準備するステップ、および
セイヨウノコギリソウフレッシュ植物圧搾汁を濃縮するステップ、
のステップを含むかまたはステップからなる、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物、好ましくは本明細書に記載の本発明の濃縮物を製造する方法に関する。
本発明は、皮膚細胞において熱ショックタンパク質および/または抗菌ペプチドの発現を刺激するためのセイヨウノコギリソウの使用を提供する。
本発明はさらに、皮膚の熱耐性を増大するためのセイヨウノコギリソウの使用を提供する。
さらに、本発明は、本発明のフレッシュ植物圧搾汁濃縮物の医薬としての使用に関する。
Furthermore, the present invention
preparing a Yarrow fresh plant press; and concentrating the Yarrow fresh plant press;
A method for producing a Yarrow fresh plant juice concentrate, preferably a concentrate of the invention as described herein, comprising or consisting of the steps of.
The present invention provides the use of Yarrow to stimulate the expression of heat shock proteins and/or antimicrobial peptides in skin cells.
The invention further provides the use of yarrow for increasing the heat tolerance of the skin.
Furthermore, the invention relates to the use of the fresh plant juice concentrate of the invention as a medicine.
驚くべきことに、セイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣の濃縮物は長い有効期間を有する。保存のための、保存剤、または昇温しての種々の処理手順、例えば低温殺菌、を除外した場合であってもそうである。本発明の方法は、穏やかな(すなわち、より高温への長期の暴露がない)成分のプロファイルを維持する方法を可能にする。特に、逆浸透、フリーズドライ、噴霧乾燥またはこれら濃縮プロセスの組合せを使用することができる。
これら方法の1つまたは複数の使用は、蒸留による水の除去などの、フレッシュ植物圧搾汁の濃縮のための好ましくない慣行を防ぐことができる。蒸留による水の除去は昇温下(70~80℃)でのより長いプロセス時間を必要とし、通常、成分プロファイルの変化につながる。熱に敏感な成分は、これにより、変化するかまたは分解されることがある。
Surprisingly, the concentrate of Yarrow fresh plant press juice dry residue has a long shelf life. This is the case even if preservatives or various processing procedures at elevated temperatures for preservation, such as pasteurization, are excluded. The method of the present invention allows for a method that maintains a mild (ie, no prolonged exposure to higher temperatures) component profile. In particular, reverse osmosis, freeze drying, spray drying or a combination of these concentration processes can be used.
The use of one or more of these methods can prevent undesirable practices for concentrating fresh plant juices, such as removing water by distillation. Removal of water by distillation requires longer process times at elevated temperatures (70-80° C.) and usually leads to changes in the component profile. Heat-sensitive components may be altered or degraded thereby.
セイヨウノコギリソウは一般に、かつ特に本発明の濃縮物およびセイヨウノコギリソウフレッシュ植物圧搾汁は、化粧用組成物に適することもまた判明している。セイヨウノコギリソウ、特にセイヨウノコギリソウフレッシュ植物圧搾汁は、いくつかの熱ショックタンパク質(HSP)を遺伝子レベルで上方制御する。例えば、HSP70は上方制御されないが、HSP27は遺伝子レベルで上方制御される。さらに、驚くべきことに、セイヨウノコギリソウ、特にセイヨウノコギリソウフレッシュ植物圧搾汁は、抗菌タンパク質およびペプチド(AMP)、例えばβ-デフェンシン1およびS100カルシウム結合タンパク質A8など、を遺伝子レベルで上方制御することが認められた。Hsp27は、熱耐性および細胞保護を与え、ストレス条件下での細胞生存を助けることが知られている。他方、AMPは、特に多剤耐性病原体の処置および皮膚および創傷感染の治療のために、局所適用される殺生物剤として使用され得る。さらに、腫瘍治療におけるその使用も考えられる。これはセイヨウノコギリソウの有利な適用、特に、好ましくは局所適用される化粧用組成物および医薬組成物の枠組みにおける適用、につながる。 It has also been found that Yarrow in general, and in particular the concentrates and Yarrow fresh plant juice of the present invention, are suitable for cosmetic compositions. Yarrow, especially Yarrow fresh plant juice, upregulates several heat shock proteins (HSPs) at the genetic level. For example, HSP70 is not upregulated, but HSP27 is upregulated at the gene level. Furthermore, it was surprisingly found that Yarrow, especially Yarrow fresh plant juice, upregulates antimicrobial proteins and peptides (AMPs), such as β-defensin 1 and S100 calcium-binding protein A8, at the genetic level. It was done. Hsp27 is known to confer heat tolerance and cytoprotection and aid cell survival under stress conditions. On the other hand, AMPs can be used as topically applied biocides, especially for the treatment of multidrug-resistant pathogens and the treatment of skin and wound infections. Furthermore, its use in tumor therapy is also envisaged. This leads to advantageous applications of yarrow, especially in the framework of cosmetic and pharmaceutical compositions, which are preferably applied topically.
本明細書で使用される用語「セイヨウノコギリソウ」は、Achillea millefolliumハーブまたはセイヨウノコギリソウハーブおよびHager's Handbuch der pharmazeutischen Praxis、Springer VerlagによるAchillea millefolliumグループのメンバーをも言う。セイヨウノコギリソウは、非処理植物としてまたは種々の調製物、例えばセイヨウノコギリソウフレッシュ植物圧搾汁またはセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物、において存在してよい。 The term "yarrow" as used herein also refers to the Achillea millefollium herb or members of the Achillea millefollium group by Yarrow Herb and Hager's Handbuch der pharmazeutischen Praxis, Springer Verlag. Yarrow may be present as an untreated plant or in various preparations, such as Yarrow fresh plant juice or Yarrow fresh plant juice concentrate.
「セイヨウノコギリソウフレッシュ植物圧搾汁」および「セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物」は、比較的高含有量のポリフェノール、特に、モノカフェオイルキナ酸群(クロロゲン酸[3-O-カフェオイルキナ酸、CAS 327-97-9]、ネオクロロゲン酸[5-O-カフェオイルキナ酸、CAS 906-33-2]およびクリプトクロロゲン酸[4-O-カフェオイルキナ酸、CAS 905-99-7]を含む)、およびジカフェオイルキナ酸群(1,5-ジ-O-カフェオイルキナ酸、[シナリン、CAS 30964-13-7]、3,4-ジ-O-カフェオイルキナ酸[イソクロロゲン酸B、CAS 14534-61-3]、3,5-ジ-O-カフェオイルキナ酸[イソクロロゲン酸A、CAS 2450-53-5]および4,5-ジ-O-ジカフェオイルキナ酸[イソクロロゲン酸C、CAS 57378-72-0]を含む)を含むフェノールカルボン酸の存在を特徴とする。ポリフェノールは、非常に優れた抗酸化効力があることで知られている。 "Yarrow fresh plant pressed juice" and "Yarrow fresh plant pressed juice concentrate" have a relatively high content of polyphenols, especially the monocaffeoylquinic acid group (chlorogenic acid [3-O-caffeoylquinic acid, CAS 327-97-9], neochlorogenic acid [5-O-caffeoylquinic acid, CAS 906-33-2] and cryptochlorogenic acid [4-O-caffeoylquinic acid, CAS 905-99-7]. ), and the dicaffeoylquinic acid group (1,5-di-O-caffeoylquinic acid, [cynarin, CAS 30964-13-7], 3,4-di-O-caffeoylquinic acid [isochlorogen acid B, CAS 14534-61-3], 3,5-di-O-caffeoylquinic acid [isochlorogenic acid A, CAS 2450-53-5] and 4,5-di-O-dicaffeoylquinic acid characterized by the presence of phenolic carboxylic acids, including [isochlorogenic acid C, CAS 57378-72-0]). Polyphenols are known for their excellent antioxidant effects.
セイヨウノコギリソウフレッシュ植物圧搾汁は、例えば、Schoenenberger社から入手できる(ユーザー向け情報:Natural unadulterated medicinal plant juice yarrow for use by adults and adolescents over 12 years of age, Walther Schoenenberger Pflanzensaftwerk GmbH & Co. KG, Magstadt (Germany), July 2014)。セイヨウノコギリソウフレッシュ植物圧搾汁は、開花期の間に収穫されたフレッシュなセイヨウノコギリソウハーブから製造される。膨満感および食欲不振を含む、消化管における軽度の痙攣性不快感に対する伝統的生薬製品として経口用途に市販されている。セイヨウノコギリソウフレッシュ植物圧搾汁は、褐色で、澄明からわずかに乳白光を帯びた液体であり、通常94.5~96.5質量%の水および3.5~5.5質量%の乾燥残渣を含有する。
セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、例えば、セイヨウノコギリソウフレッシュ植物圧搾汁から、濃縮プロセスによって製造されてよい。例えば、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、Schoenenberger社のセイヨウノコギリソウフレッシュ植物圧搾汁から、濃縮によって製造される。しかし、いかなるセイヨウノコギリソウ抽出物、特にセイヨウノコギリソウフレッシュ植物圧搾汁も使用することができることが明らかである。
Yarrow fresh plant juice is available for example from Schoenenberger (Information for users: Natural unadulterated medicinal plant juice yarrow for use by adults and adolescents over 12 years of age, Walther Schoenenberger Pflanzensaftwerk GmbH & Co. KG, Magstadt (Germany) ), July 2014). Yarrow fresh plant juice is produced from fresh Yarrow herb harvested during the flowering period. It is marketed for oral use as a traditional herbal product for mild spasmodic discomfort in the gastrointestinal tract, including bloating and loss of appetite. Yarrow fresh plant juice is a brown, clear to slightly opalescent liquid that typically contains 94.5-96.5% water and 3.5-5.5% dry residue by weight. contains.
Yarrow fresh plant juice concentrate may be produced, for example, from Yarrow fresh plant juice by a concentration process. For example, Yarrow fresh plant juice concentrate is produced from Schoenenberger Yarrow fresh plant juice by concentration. However, it is clear that any Yarrow extract can be used, especially Yarrow fresh plant juice.
用語「乾燥残渣」または「乾燥物質」は、分析化学の定義に従って、乾燥後に残留している物質の、例えばセイヨウノコギリソウフレッシュ植物圧搾汁またはセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の、水および/または溶媒フリーのフラクションに対して使用される。乾燥プロセスは、本質的に完全であり、すなわち分析される物質、例えばセイヨウノコギリソウフレッシュ植物圧搾汁またはセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物、の残留水および/または溶媒含有量は、好ましくは≦1質量%、好ましくは≦0.5質量%、≦0.1質量%、より好ましくは≦0.01質量%である。乾燥は、好ましくは、穏やかなプロセス、例えば、水、溶媒または該当する場合、溶媒混合物、の沸点よりもわずかに高い温度、例えば≦10℃、≦5℃または≦2℃など、で行われる。代替の乾燥方法には、フリーズドライ、部分真空下での乾燥、乾燥剤の使用、または前記方法の組合せが含まれる。 The term "dry residue" or "dry substance" refers to the substances remaining after drying, such as water and/or solvents of Yarrow fresh plant press juice or Yarrow fresh plant press concentrate, according to the definition of analytical chemistry. Used for free fractions. The drying process is essentially complete, i.e. the residual water and/or solvent content of the substance to be analyzed, such as Yarrow fresh plant juice or Yarrow fresh plant juice concentrate, is preferably ≦1 mass %, preferably ≦0.5% by weight, ≦0.1% by weight, more preferably ≦0.01% by weight. Drying is preferably carried out in a mild process, for example at a temperature slightly above the boiling point of the water, solvent or solvent mixture, if applicable, such as ≦10°C, ≦5°C or ≦2°C. Alternative drying methods include freeze drying, drying under partial vacuum, use of a desiccant, or a combination of the above methods.
本明細書で使用される用語「抽出物」は、植物物質、特にセイヨウノコギリソウの増粘または乾燥された抽出物に関する。したがって、抽出物は液体である。セイヨウノコギリソウフレッシュ植物圧搾汁は、こうした抽出物を表す。セイヨウノコギリソウフレッシュ植物圧搾汁は、好ましくは、≦8質量%の乾燥残渣、好ましくは≦7.5質量%の乾燥残渣、≦7質量%の乾燥残渣、≦6.5質量%の乾燥残渣、≦6質量%の乾燥残渣、または≦5.5質量%の乾燥残渣を含む。より好ましくは、セイヨウノコギリソウフレッシュ植物圧搾汁は、3.5質量%~5.5質量%の乾燥残渣を含む。 The term "extract" as used herein relates to thickened or dried extracts of plant material, particularly yarrow. Therefore, the extract is a liquid. Yarrow fresh plant juice represents such an extract. Yarrow fresh plant juice preferably contains ≦8% by weight dry residue, preferably ≦7.5% by weight dry residue, ≦7% by weight dry residue, ≦6.5% by weight dry residue, ≦ Contains 6% by weight dry residue, or ≦5.5% by weight dry residue. More preferably, the Yarrow fresh plant juice comprises from 3.5% to 5.5% by weight dry residue.
本明細書で使用される用語「濃縮物」は、比較的低比率の追加のフィラーおよび/または溶媒を含む固体または液体に関する。したがって、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、セイヨウノコギリソウフレッシュ植物圧搾汁よりも高含量の乾燥残渣を特徴とする。セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、≧10質量%の乾燥残渣、好ましくは≧15質量%の乾燥残渣、≧20質量%の乾燥残渣、≧25質量%の乾燥残渣、≧30質量%の乾燥残渣、≧40質量%の乾燥残渣、≧50質量%の乾燥残渣、≧60質量%の乾燥残渣、≧70質量%の乾燥残渣、≧80質量%の乾燥残渣、または≧90質量%の乾燥残渣を有する。濃縮物は、穏やかに製造され、すなわち抽出物と比較して、本質的に同一の構成要素の含量スペクトルが(乾燥残渣抽出によって分割される乾燥残渣濃縮物の比率に従って)適切に濃縮されて残存する。本質的に、構成要素の同一の含量スペクトルは、濃縮物中±10質量%の、好ましくは濃縮物中±5質量%の、より好ましくは濃縮物中±2質量%の、構成要素の個々の偏差に関連する。例えば、セイヨウノコギリソウフレッシュ植物圧搾汁が、8質量%の乾燥残渣を有し、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物が≧10質量%の乾燥残渣を有する場合には、濃縮物中の個々の構成要素または成分の濃度は、少なくとも10を8で割った因数だけ増大される。 The term "concentrate" as used herein relates to solids or liquids containing relatively low proportions of additional fillers and/or solvents. Thus, Yarrow fresh plant juice concentrate is characterized by a higher content of dry residue than Yarrow fresh plant juice. Yarrow fresh plant juice concentrate contains ≧10% by weight dry residue, preferably ≧15% by weight dry residue, ≧20% by weight dry residue, ≧25% by weight dry residue, ≧30% by weight dry residue, ≧40% by weight dry residue, ≧50% by weight dry residue, ≧60% by weight dry residue, ≧70% by weight dry residue, ≧80% by weight dry residue, or ≧90% by weight dry residue. has. Concentrates are produced in a gentle manner, i.e. in comparison with extracts, the content spectrum of essentially the same constituents remains suitably concentrated (according to the ratio of dry residue concentrate divided by dry residue extraction). do. Essentially, the same content spectrum of the constituents is determined by the individual content of the constituents of ±10% by weight in the concentrate, preferably ±5% by weight in the concentrate, more preferably ±2% by weight in the concentrate. related to deviation. For example, if the Yarrow fresh plant juice has a dry residue of 8% by weight and the Yarrow fresh plant juice concentrate has a dry residue of ≧10% by weight, then the individual components in the concentrate or the concentration of the component is increased by at least a factor of 10 divided by 8.
固体セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物に対して、10~100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~90質量%の水、および100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物に対して0~90質量%の担体を含む。好ましくは、固体セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、直接に、すなわち前濃縮なしに、本明細書で言及する担体の任意選択での添加により製造される。こうした固体セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、10~100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~10質量%の水、および0~90質量%の担体を含む。より好ましくは、固体セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、10~50質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~10質量%の水、および50~90質量%の担体を含む。 The solid Yarrow fresh plant pressed juice concentrate contains 100% by mass of Yarrow fresh plant pressed juice concentrate, 10 to 100% by mass of Yarrow fresh plant pressed juice dry residue, 0 to 90% by mass of water, and 0 to 90% by weight of carrier based on 100% by weight of Yarrow fresh plant pressed juice concentrate. Preferably, the solid Yarrow fresh plant juice concentrate is produced directly, ie without pre-concentration, with the optional addition of the carriers mentioned herein. Such a solid Yarrow fresh plant juice concentrate comprises 10-100% by weight of Yarrow fresh plant juice dry residue, 0-10% by weight water, and 0-90% by weight of carrier. More preferably, the solid Yarrow fresh plant press concentrate comprises 10-50% by weight of Yarrow fresh plant press dry residue, 0-10% by weight water, and 50-90% by weight of carrier.
液体セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、好ましくは、逆浸透および続いての液体担体の添加によって製造され、好ましくは10~70質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~90質量%の水、0~90質量%の液体担体、および0~5質量%の保存剤および/または安定化剤を含む。任意選択の液体担体は、後述の通りであり、例えばグリセロール、プロピレングリコール、ブチレングリコール、1,3-プロパンジオール、1,2-ペンタンジオール、1,2-ヘキサンジオールであるかまたはこれらを含み、かつ、濃縮後に、任意選択の保存剤および/または安定化剤もまた添加される。
好ましいのは、10~50質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~90質量%の水、0~50質量%の担体、および0~3質量%の保存剤および/または安定化剤を含む液体セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物である。固体または液体セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の利点は、簡潔かつ費用効率の良い製造、良好な保存性、容易な取扱いおよび投与、ならびに、所望されれば、標準化である。
化粧用組成物、特に皮膚および毛髪のクレンジングおよびケアのための化粧用組成物、における(固体または液体)セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の用量は、0.0001~10質量%、好ましくは0.001~5質量%、特に好ましくは0.005~3質量%である。
The liquid Yarrow fresh plant press juice concentrate is preferably produced by reverse osmosis and subsequent addition of a liquid carrier, preferably from 10 to 70% by weight of Yarrow fresh plant press dry residue, from 0 to 90% by weight. of water, 0-90% by weight of liquid carrier, and 0-5% by weight of preservatives and/or stabilizers. Optional liquid carriers are as described below and include, for example, glycerol, propylene glycol, butylene glycol, 1,3-propanediol, 1,2-pentanediol, 1,2-hexanediol, And after concentration, optional preservatives and/or stabilizers are also added.
Preference is given to 10 to 50% by weight of Yarrow fresh plant juice dry residue, 0 to 90% by weight of water, 0 to 50% by weight of carrier, and 0 to 3% by weight of preservatives and/or stabilizers. is a liquid yarrow fresh plant pressed juice concentrate containing. The advantages of solid or liquid Yarrow fresh plant juice concentrate are simple and cost-effective production, good shelf life, easy handling and administration, and, if desired, standardization.
The dosage of yarrow fresh plant juice concentrate (solid or liquid) in cosmetic compositions, especially cosmetic compositions for cleansing and care of the skin and hair, is from 0.0001 to 10% by weight, preferably 0. 0.001 to 5% by weight, particularly preferably 0.005 to 3% by weight.
化粧用組成物は、好ましくは、0.0001~10質量%、好ましくは0.001~5質量%、特に好ましくは0.005~3質量%のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を含み、ここで濃縮物はフリーズドライ、噴霧乾燥または逆浸透によって得られてよい。これら化粧用組成物はまた、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物以外の各々の成分の個々の量を自由に選択することができる例5、表12、組成物1~11に記載の成分の組合せのうちの1つを含む。使用される香料の組合せは、香油PFO1およびPFO2に限定されるものではなく、当業者に公知の他の香料または香料の組合せを使用し得ることは明らかである。 The cosmetic composition preferably comprises from 0.0001 to 10% by weight, preferably from 0.001 to 5% by weight, particularly preferably from 0.005 to 3% by weight of Yarrow fresh plant juice concentrate, wherein The concentrate may be obtained by freeze drying, spray drying or reverse osmosis. These cosmetic compositions may also contain combinations of ingredients as described in Example 5, Table 12, Compositions 1 to 11, with the freedom to choose the individual amounts of each ingredient other than Yarrow fresh plant juice concentrate. Contains one of the following. It is clear that the combination of perfumes used is not limited to the perfume oils PFO1 and PFO2, but other perfumes or combinations of perfumes known to the person skilled in the art can be used.
別法として、ゲル歯磨きペーストを示すことができる。ゲル歯磨きペーストきもまた、0.0001~10質量%、好ましくは0.001~5質量%、特に好ましくは0.005~3質量%のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を含み、ここで濃縮物はフリーズドライ、噴霧乾燥または逆浸透によって得られてよい。この組成物はまた、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物以外の各々の成分の個々の量を自由に選択することができる例5、表13、組成物I、IIおよびIIIに記載の成分の組合せのうちの1つを含む。 Alternatively, a gel toothpaste can be presented. The gel toothpaste also contains from 0.0001 to 10% by weight, preferably from 0.001 to 5% by weight, particularly preferably from 0.005 to 3% by weight of Yarrow fresh plant juice concentrate, where the concentrate may be obtained by freeze drying, spray drying or reverse osmosis. This composition also combines the ingredients described in Example 5, Table 13, Compositions I, II and III, with the freedom to choose the individual amounts of each ingredient other than Yarrow fresh plant juice concentrate. Contains one of the following.
別法として、そのまま使用できるフッ化物入りマウスウォッシュを示すことができる。そのまま使用できるフッ化物入りマウスウォッシュもまた、0.0001~10質量%、好ましくは0.001~5質量%、特に好ましくは0.005~3質量%のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を含み、ここで濃縮物はフリーズドライ、噴霧乾燥または逆浸透によって得られてよい。この組成物はまた、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物以外の各々の成分の個々の量を自由に選択することができる例5、表14、組成物I、IIおよびIIIに記載の成分の組合せのうちの1つを含む。 Alternatively, ready-to-use fluoride mouthwashes can be presented. The ready-to-use fluoride mouthwash also comprises from 0.0001 to 10% by weight, preferably from 0.001 to 5% by weight, particularly preferably from 0.005 to 3% by weight of Yarrow fresh plant juice concentrate. , where the concentrate may be obtained by freeze drying, spray drying or reverse osmosis. This composition also combines the ingredients described in Example 5, Table 14, Compositions I, II and III, with the freedom to choose the individual amounts of each ingredient other than Yarrow fresh plant juice concentrate. Contains one of the following.
別法として、本発明のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、言及された成分からなる。この場合、他の成分は存在しない。したがって、本発明のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物に対して、10~100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~90質量%の水、および0~90質量%の担体からなる。好ましくは、本発明のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、10~50質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~50質量%の水、および0~50質量%の担体;10~20質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~80質量%の水、および0~80質量%の担体;10~15質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、0~85質量%の水、および0~85質量%の担体、からなる。より好ましくは、本発明のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、10~15質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、ならびに85~95質量%の水および/または担体からなる。
一実施形態によれば、担体は、固体担体、特に、マルトデキストリン、デキストリンまたはシクロデキストリン、および/または液体担体、特に、グリセロール、プロピレングリコール、ブチレングリコール、1,3-プロパンジオール、1,2-ペンタンジオール、1,2-ヘキサンジオールまたは1,2-オクタンジオールである。
Alternatively, the Yarrow fresh plant juice concentrate of the present invention consists of the mentioned ingredients. In this case no other ingredients are present. Therefore, the Yarrow fresh plant pressed juice concentrate of the present invention contains 100% by weight of Yarrow fresh plant pressed juice concentrate, 10 to 100% by weight of Yarrow fresh plant pressed juice dry residue, and 0 to 90% by weight. % water, and 0 to 90% by weight carrier. Preferably, the Yarrow fresh plant juice concentrate of the present invention comprises 10 to 50% by weight of Yarrow fresh plant juice dry residue, 0 to 50% by weight of water, and 0 to 50% by weight of carrier; 20% by weight of Yarrow fresh plant pressed juice dried residue, 0-80% by weight of water and 0-80% by weight of carrier; 10-15% by weight of Yarrow fresh plant pressed juice dried residue, 0-85% by weight of water and 0 to 85% by weight of carrier. More preferably, the Yarrow fresh plant press concentrate of the present invention consists of 10-15% by weight of Yarrow fresh plant press dry residue and 85-95% by weight of water and/or carrier.
According to one embodiment, the carrier is a solid carrier, in particular maltodextrin, dextrin or cyclodextrin, and/or a liquid carrier, in particular glycerol, propylene glycol, butylene glycol, 1,3-propanediol, 1,2- Pentanediol, 1,2-hexanediol or 1,2-octanediol.
担体または担体材料の添加は、製品特性(例えば、流動性)および/またはある程度まで影響される標準化を可能にする。さらに、生成するマトリックス粒子もまた、不安定な成分に対するある種の保護を与える。担体は好ましくは、濃縮の過程において使用されるようなものから選択される。例えば、濃縮が噴霧乾燥によって行われる場合、固体担体、特に以下に列挙する多糖は、適切な材料として使用されてよい。この多糖は次には、化粧用組成物において、担体、例えば組成物に所望の特性を与える担体、として働く。より好ましくは、担体物質は、所望の投与形態において、例えば化粧用組成物、医薬組成物、食品組成物または補助食品に使用される濃縮物の状況において使用される。
1つまたはいくつかの担体が含まれてよいことは明らかである。これらの担体は、固体または液体(25℃および1013ミリバールにおいて)であってよい。各々の物質または物質の混合物は担体として使用されてよい。
The addition of carriers or carrier materials allows the product properties (eg flowability) and/or the standardization to be influenced to a certain extent. Additionally, the resulting matrix particles also provide some protection against unstable components. The carrier is preferably selected from those used in the concentration process. For example, if concentration is carried out by spray drying, solid carriers, especially the polysaccharides listed below, may be used as suitable materials. This polysaccharide then serves as a carrier in the cosmetic composition, eg, a carrier that imparts desired properties to the composition. More preferably, the carrier substance is used in the desired dosage form, for example in the context of a concentrate for use in cosmetic compositions, pharmaceutical compositions, food compositions or food supplements.
It is clear that one or several carriers may be included. These carriers may be solid or liquid (at 25° C. and 1013 mbar). Individual substances or mixtures of substances may be used as carriers.
有利な固体担体は、分解デンプン、化学的または物理的に修飾されたデンプン、修飾セルロース、アラビアガム、ガティガム、トラガント、カラヤ、カラギーナン、グアーガム、ローカストビーンガム、アルギネート、ペクチン、イヌリンまたはキサンタンガムである。一般に、例えばマルトデキストリン、デキストリン、酸化デンプンまたは乳糖、コラーゲン、フュームドシリカ(例えばAerosil(登録商標)など)、カシューガム、アラビアガムまたは類似のものなどの多糖が使用されてよい。前述の固体担体の混合物もまた、本発明の状況において使用されてよい。マルトデキストリンは、特に好ましい固体担体である。
デンプンの分解の度合いは、通常、指標「デキストロース当量」(DE)によって示され、この指標は長鎖グルコースポリマーに対して0の閾値かつ純粋グルコースに対して100の閾値を有する。多糖、特に、5~20の範囲のDE値、好ましくは15~20の範囲DE値をもつマルトデキストリンが、やはり特に有利である。
好ましい液体担体の例は、エタノール、ジアセチン、イソプロピルアルコール、グリセロール、1,2-プロピレングリコール、1,3-プロパンジオール、1,3-ブチレングリコール、トリアセチンおよびそれらの混合物である。
Preferred solid carriers are degraded starches, chemically or physically modified starches, modified celluloses, gum arabic, gum ghatti, tragacanth, karaya, carrageenan, guar gum, locust bean gum, alginates, pectin, inulin or xanthan gum. Generally, polysaccharides such as maltodextrin, dextrin, oxidized starch or lactose, collagen, fumed silica (such as Aerosil®), cashew gum, gum arabic or the like may be used. Mixtures of the aforementioned solid carriers may also be used in the context of the present invention. Maltodextrin is a particularly preferred solid carrier.
The degree of starch degradation is usually indicated by the index "dextrose equivalent" (DE), which has a threshold of 0 for long-chain glucose polymers and 100 for pure glucose. Polysaccharides, especially maltodextrins with a DE value in the range 5-20, preferably in the range 15-20, are again particularly advantageous.
Examples of preferred liquid carriers are ethanol, diacetin, isopropyl alcohol, glycerol, 1,2-propylene glycol, 1,3-propanediol, 1,3-butylene glycol, triacetin and mixtures thereof.
本発明の好ましい(好ましくは噴霧乾燥された)濃縮物において有利な担体は、特に、二酸化ケイ素(ケイ酸、シリカゲル)、炭水化物および/または炭水化物ポリマー(多糖)、シクロデキストリン、デンプン、分解デンプン(デンプン加水分解物)、化学的または物理的に修飾されたデンプン、修飾セルロース、アラビアガム、ガティガム、トラガント、カラヤ、カラギーナン、グアーガム、ローカストビーンガム、アルギネート、ペクチン、イヌリンまたはキサンタンガムである。好ましいデンプン加水分解物は、マルトデキストリンおよびデキストリンである。特に好ましい担体は、二酸化ケイ素、アラビアガムおよびマルトデキストリンであり、ここで5~20の範囲のDE値を有するマルトデキストリンが好ましい。 Advantageous carriers in the preferred (preferably spray-dried) concentrates of the invention are in particular silicon dioxide (silicic acid, silica gel), carbohydrates and/or carbohydrate polymers (polysaccharides), cyclodextrins, starches, degraded starches (starch hydrolysates), chemically or physically modified starches, modified celluloses, gum arabic, gum ghatti, tragacanth, karaya, carrageenan, guar gum, locust bean gum, alginates, pectin, inulin or xanthan gum. Preferred starch hydrolysates are maltodextrins and dextrins. Particularly preferred carriers are silicon dioxide, gum arabic and maltodextrins, with maltodextrins having DE values in the range from 5 to 20 being preferred.
好ましいまたは特に好ましい担体はまた、無味であるかまたは本質的に無味であるという利点をも有する。結果として、これらの前駆物質は、他の官能特性、特に芳香および味覚プロファイル(マスクされるべき不快な味覚印象は別にして)に対して、影響しないかまたは有意には影響しないところから、本発明の濃縮物は、数多くの多様な製品タイプおよび調製物において使用され得る。
一実施形態によれば、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、さらに、保存剤および/または安定化剤を含む。
いかなる数の保存剤および/または安定化剤が使用されてもよい。
本発明の状況において使用される保存剤は、通常、以下の特性のいくつか、好ましくは全てを有する。それらは、毒物学的に無害であり、皮膚の忍容性良好であり、安定で、本質的に完全に無臭であり、かつ容易にかつ費用が掛からずに(すなわち容易に入手可能な抽出物から)製造できる。保存剤はまた、抗菌特性をも有する。適切な保存剤は、例えば、WO2006/045743において見られる。
Preferred or particularly preferred carriers also have the advantage of being tasteless or essentially tasteless. As a result, these precursors can range from having no or not significantly affecting other organoleptic properties, in particular aroma and taste profiles (apart from unpleasant taste impressions to be masked), to The concentrates of the invention can be used in a number of different product types and preparations.
According to one embodiment, the Yarrow fresh plant juice concentrate further comprises preservatives and/or stabilizers.
Any number of preservatives and/or stabilizers may be used.
Preservatives used in the context of the present invention typically have some, preferably all, of the following properties: They are toxicologically harmless, well tolerated by the skin, stable, essentially completely odorless, and easily and inexpensively (i.e., readily available extractables). ) can be manufactured. Preservatives also have antimicrobial properties. Suitable preservatives are found, for example, in WO2006/045743.
適切な保存剤の例は、安息香酸、安息香酸のエステルおよび塩、ソルビン酸およびその塩、プロピオン酸およびその塩、サリチル酸およびその塩、ドルムアルデヒドおよびパラホルムアルデヒド、2-ヒドロキシビフェニルエーテルおよびその塩、2-亜鉛スルフィドピリジンN-オキシド、無機サルファイトおよびビサルファイト、ヨウ素酸ナトリウム、クロロブタノール、4-エチル水銀(II)-5-アミノ-1,3-ビス(2-ヒドロキシ安息香酸)、そのエステルおよび塩、デヒドロキシ酢酸、ギ酸、1,6-ビス(4-アミノジノ-2-ブロモフェノキシ)-n-ヘキサンおよびその塩、エチル水銀(II)-チオサリチル酸のナトリウム塩、フェニル水銀およびその塩、10-ウンデシレン酸およびその塩、5-アミノ-1,3-ビス(2-エチルヘキシル)-5-メチルヘキサヒドロピリミジン、5-ブロモ-5-ニトロ-1,3-ジオキサン、2-ブロモ-2-ニトロ-1,3-プロパンジオール、2,4-ジクロロベンジルアルコール、N-(4-クロロフェニル)-N’-(3,4-ジクロロフェニル)尿素、4-クロロ-m-クレゾール、2,4,4’- トリクロロ-2’-ヒドロキシジフェニルエーテル、4-クロロ-3,5-ジメチルフェノール、1,1’-メチレン-ビス(3-(1-ヒドロキシメチル-2,4-ジオキソイミダゾリジン-5-イル)尿素)、ポリ(ヘキサメチレンビグアナイド)塩酸塩、2-フェノキシエタノール、ヘキサメチレンテトラミン、1(3-クロロアリル)-3,5,7-トリアザ-1-アゾニアアダマンタンクロリド、1(4-クロロフェノキシ)1(1H-イミダゾール-1-イル)-3,3-ジメチル-2-ブタノン、1,3-ビス(ヒドロキシメチル)-5,5-ジメチル-2,4-イミダゾリジンジオン、ベンジルアルコール、オクトピロックス、1,2-ジブロモ-2,4-ジシアノブタン、2,2’-メチレン-ビス(6-ブロモ-4-クロロフェノール)、ブロモクロロフェン、5-クロロ-2-メチル-3(2H)イソチアゾリノンおよび2-メチル-3(2H)イソチアゾリノンの塩化マグネシウムおよび硝酸マグネシウムとの混合物、2-ベンジル-4-クロロフェノール、2-クロロアセトアミド、クロルヘキシジン、酢酸クロルヘキシジン、グルコン酸クロルヘキシジン、塩酸クロルヘキシジン、1-フェノキシプロパン-2-オール、N-アルキル(C12-C22)トリメチルアンモニウムブロミドおよびクロリド、4,4-ジメチル-1,3-オキサゾリジン、N-ヒドロキシメチル-N-(1,3-ジ(ヒドロキシメチル)-2,5-ジオキソイミダゾリジン-4-イル)-N’-ヒドロキシメチル尿素、1,6-ビス(4-アミジノフェノキシ)-n-ヘキサンおよびその塩、グルタルアルデヒド、5-エチル-1-アザ-3,7-ジオキサビシクロ(3.3.0)オクタン、3-(4-クロロフェノキシ)-1,2-プロパンジオール、ハイアミン、アルキル-(C8-C18)-ジメチルベンジルアンモニウムクロリド、アルキル-(C8-C18)-ジメチルベンジルアンモニウムブロミド、アルキル-(C8-C18)-ジメチルベンジルアンモニウムサッカリネート、ベンジルヘミホルマール、o-シメン-5-オール、ヒドロキシメチルアミノ酢酸ナトリウムまたはヒドロキシメチルアミノ酢酸ナトリウム、ならびに前述の物質の混合物、を含む。 Examples of suitable preservatives are benzoic acid, esters and salts of benzoic acid, sorbic acid and its salts, propionic acid and its salts, salicylic acid and its salts, dormaldehyde and paraformaldehyde, 2-hydroxybiphenyl ether and its salts, 2-Zinc sulfide pyridine N-oxide, inorganic sulfite and bisulfite, sodium iodate, chlorobutanol, 4-ethylmercury(II)-5-amino-1,3-bis(2-hydroxybenzoic acid), its esters and salt, dehydroxyacetic acid, formic acid, 1,6-bis(4-aminodino-2-bromophenoxy)-n-hexane and its salts, sodium salt of ethylmercury(II)-thiosalicylic acid, phenylmercury and its salts, 10 -Undecylenic acid and its salts, 5-amino-1,3-bis(2-ethylhexyl)-5-methylhexahydropyrimidine, 5-bromo-5-nitro-1,3-dioxane, 2-bromo-2-nitro -1,3-propanediol, 2,4-dichlorobenzyl alcohol, N-(4-chlorophenyl)-N'-(3,4-dichlorophenyl)urea, 4-chloro-m-cresol, 2,4,4' - Trichloro-2'-hydroxydiphenyl ether, 4-chloro-3,5-dimethylphenol, 1,1'-methylene-bis(3-(1-hydroxymethyl-2,4-dioxoimidazolidin-5-yl) urea), poly(hexamethylene biguanide) hydrochloride, 2-phenoxyethanol, hexamethylenetetramine, 1(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride, 1(4-chlorophenoxy)1 (1H-imidazol-1-yl)-3,3-dimethyl-2-butanone, 1,3-bis(hydroxymethyl)-5,5-dimethyl-2,4-imidazolidinedione, benzyl alcohol, octopirox , 1,2-dibromo-2,4-dicyanobutane, 2,2'-methylene-bis(6-bromo-4-chlorophenol), bromochlorophene, 5-chloro-2-methyl-3(2H) isothiazolinone and mixtures of 2-methyl-3(2H) isothiazolinone with magnesium chloride and magnesium nitrate, 2-benzyl-4-chlorophenol, 2-chloroacetamide, chlorhexidine, chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, 1-phenoxypropane -2-ol, N-alkyl (C12-C22) trimethylammonium bromide and chloride, 4,4-dimethyl-1,3-oxazolidine, N-hydroxymethyl-N-(1,3-di(hydroxymethyl)-2) , 5-dioxoimidazolidin-4-yl)-N'-hydroxymethylurea, 1,6-bis(4-amidinophenoxy)-n-hexane and its salts, glutaraldehyde, 5-ethyl-1-aza- 3,7-dioxabicyclo(3.3.0)octane, 3-(4-chlorophenoxy)-1,2-propanediol, high amine, alkyl-(C8-C18)-dimethylbenzylammonium chloride, alkyl-( C8-C18)-dimethylbenzylammonium bromide, alkyl-(C8-C18)-dimethylbenzylammonium saccharinate, benzyl hemiformal, o-cymen-5-ol, sodium hydroxymethylaminoacetate or sodium hydroxymethylaminoacetate, and mixtures of the aforementioned substances.
他の適切な保存剤には、パラベンが含まれる。パラベンは、メチルパラベン、エチルパラベン、n-プロピルパラベン、n-ブチルパラベン、イソブチルパラベン、および混合物などのパラヒドロキシ安息香酸のエステルである。パラベンは、単独でまたは組み合わせて、保存剤として、特に化粧用組成物および医薬組成物において使用されてよい。前述の組成物に関して好ましいパラベンの組合せは、18質量%のメチルパラベンおよび0.02質量%のプロピルパラベンを含む。パラベンは、抗菌効果および殺真菌効果の両方を有する。 Other suitable preservatives include parabens. Parabens are esters of parahydroxybenzoic acid such as methylparaben, ethylparaben, n-propylparaben, n-butylparaben, isobutylparaben, and mixtures. Parabens, alone or in combination, may be used as preservatives, especially in cosmetic and pharmaceutical compositions. A preferred paraben combination for the aforementioned composition comprises 18% by weight methylparaben and 0.02% by weight propylparaben. Parabens have both antibacterial and fungicidal effects.
さらに、本発明によれば、一般に化粧品に使用される保存剤または保存賦形剤は適切であり、例えば、ジブロモジシアノブタン(2-ブロモ-2-ブロモメチルグルタロジニトリル)、3-ヨード-2-プロピニルブチルカルバメート、2-ブロモ-2-ニトロプロパン-1,3-ジオール、イミダゾリジニル尿素、5-クロロ-2-メチル-4-イソチアゾリン-3-オン、2-クロロアセトアミド、塩化ベンザルコニウム、ベンジルアルコールおよびホルムアルデヒドスプリッターである。
さらに、フェニルヒドロキシアルキルエーテル、特にフェノキシエタノールとして知られる化合物は、いくつかの微生物に対するその殺菌および殺真菌効果のために、保存剤として適している。
Furthermore, according to the invention, preservatives or preservative excipients commonly used in cosmetics are suitable, for example dibromodicyanobutane (2-bromo-2-bromomethylglutarodinitrile), 3-iodo-2 -Propynylbutyl carbamate, 2-bromo-2-nitropropane-1,3-diol, imidazolidinyl urea, 5-chloro-2-methyl-4-isothiazolin-3-one, 2-chloroacetamide, benzalkonium chloride, benzyl Alcohol and formaldehyde splitter.
Furthermore, phenylhydroxyalkyl ethers, especially the compound known as phenoxyethanol, are suitable as preservatives due to their bactericidal and fungicidal effects against some microorganisms.
安定化剤は、本発明の組成物を外的環境の影響から保護するために、本発明の状況において使用される。こうした環境影響には、例えば、大気中の酸素および光照射、特に日光が含まれる。大気中の酸素の酸化作用は、例えば、適切な抗酸化剤によって減殺することができる。光安定化剤は光照射の有害な影響を減殺するために使用されてよい。 Stabilizers are used in the context of the invention to protect the compositions of the invention from the effects of the external environment. Such environmental influences include, for example, atmospheric oxygen and light radiation, especially sunlight. The oxidizing effect of atmospheric oxygen can be counteracted, for example, by suitable antioxidants. Light stabilizers may be used to counteract the deleterious effects of light radiation.
いくつかの安息香酸およびそれらの塩の保護効果は、昔から知られている。これらは、主として酸性での利用における微生物学的安定化のためにとりわけ食品に使用され、E210(安息香酸)、E211(安息香酸ナトリウム)、E212(安息香酸カリウム)およびE213(安息香酸カルシウム)として知られている。また種々のパラベン(ヒドロキシ安息香酸エステル)も、E214(p-ヒドロキシ安息香酸エチル)、E215(p-ヒドロキシ安息香酸エチルナトリウム)、E218(p-ヒドロキシ安息香酸メチル)、およびE219(p-ヒドロキシ安息香酸メチルナトリウム)の番号で、微生物学的安定性を改善するために食品において使用される(BGBI. I 2000, 1537-1545)。この物質クラスはまた、(微生物学的)安定性を改善する目的で化粧品においても幅広く使用される。
適切な安定化剤はまた、例えば、DE29924656、DE69917811、DE69624799、EP2952103(欧州特許出願公開第2952103号)およびDE69518581から採り上げることができる。
一実施形態によれば、セイヨウノコギリソウフレッシュ植物圧搾汁は、<60℃の温度で濃縮される。
The protective effects of some benzoic acids and their salts have been known for a long time. They are used inter alia in foods for microbiological stabilization in primarily acidic applications and as E210 (benzoic acid), E211 (sodium benzoate), E212 (potassium benzoate) and E213 (calcium benzoate). Are known. Various parabens (hydroxybenzoic acid esters) are also used, including E214 (ethyl p-hydroxybenzoate), E215 (ethyl sodium p-hydroxybenzoate), E218 (methyl p-hydroxybenzoate), and E219 (p-hydroxybenzoic acid ester). (BGBI. I 2000, 1537-1545). This substance class is also widely used in cosmetics for the purpose of improving (microbiological) stability.
Suitable stabilizers can also be taken from, for example, DE 29924656, DE 69917811, DE 69624799, EP 2952103 (EP 2952103) and DE 69518581.
According to one embodiment, the Yarrow fresh plant juice is concentrated at a temperature of <60°C.
濃縮は常圧(1013ミリバール)下または部分的陰圧下、例えば100~1000ミリバール、好ましくは200~500ミリバールで行われてよい。好ましくは、セイヨウノコギリソウフレッシュ植物圧搾汁の濃縮は、<55℃の温度、より好ましくは<50℃、<45℃、<40℃、<35℃、<30℃、<25℃、さらにより好ましくは<10℃、<0℃、または<20℃で行われる。部分的陰圧と低温との組合せは、濃縮物の穏やかな処理であるから、特に好ましい。
一実施形態によれば、セイヨウノコギリソウフレッシュ植物圧搾汁は、フリーズドライ、噴霧乾燥および逆浸透、またはこれらの組合せから選択される濃縮プロセスによって濃縮される。これらのプロセスは、技術水準において周知である。
Concentration may be carried out under normal pressure (1013 mbar) or under partially negative pressure, for example between 100 and 1000 mbar, preferably between 200 and 500 mbar. Preferably, the concentration of Yarrow fresh plant juice is carried out at a temperature of <55°C, more preferably <50°C, <45°C, <40°C, <35°C, <30°C, <25°C, even more preferably Performed at <10°C, <0°C, or <20°C. The combination of partial negative pressure and low temperature is particularly preferred since it is a gentle treatment of the concentrate.
According to one embodiment, the Yarrow fresh plant juice is concentrated by a concentration process selected from freeze drying, spray drying and reverse osmosis, or a combination thereof. These processes are well known in the art.
逆浸透は、水溶液の穏やかな濃縮であるところから、本発明の水ベース抽出物/汁濃縮物の製造にとって、特に有利であることが示されている。超ろ過としても知られる逆浸透は、通常、NaCl排除率が、≧90%、好ましくは≧95%、≧97%、より好ましくは99%であるPAN(ポリアクリロニトリル)、PES(ポリエーテルスルホン)および/またはPVDF(ポリ二フッ化ビニリデン)の膜により、操作流量8l/m2/時~34l/m2/時、好ましくは8l/m2/時~25l/m2/時、8l/m2/時~20l/m2/時圧、より好ましくは8l/m2/時~15l/m2/時、圧力15~50bar、好ましくは15~40bar、より好ましくは15~35bar、および温度≦60℃、好ましくは≦50℃、≦40℃、より好ましくは≦30℃において、行われる。
これらの濃縮物を微生物汚染から守ることもまた有利である。これは、例えば、pH値を下げることおよび/または前述のような適切な保存剤の添加によって達成することができる。
凍結乾燥または昇華乾燥とも称されるフリーズドライは、費用集約的で比較的複雑ではあるが、極度に穏やかなプロセスである。フリーズドライは、昇華の物理的プロセスに基づいている:このプロセスにより氷の結晶が、中間に液相の出現を伴わずに、直接、気体状態へと昇華する。本事例において、フリーズドライは、保存剤の添加がなくても十分に貯蔵できる固体を生成する。フリーズドライの手順は、例えば、GB1447988およびDE19817177から採り上げることができる。
Reverse osmosis has been shown to be particularly advantageous for the production of the water-based extract/juice concentrates of the present invention because it is a gentle concentration of aqueous solutions. Reverse osmosis, also known as ultrafiltration, typically uses PAN (polyacrylonitrile), PES (polyethersulfone) with a NaCl rejection rate of ≧90%, preferably ≧95%, ≧97%, more preferably 99%. and/or PVDF (polyvinylidene difluoride) membranes for operating flow rates of 8 l/m 2 /h to 34 l/m 2 /h, preferably 8 l/m 2 /h to 25 l/m 2 /h, 8 l/m 2 /h to 20 l/m 2 /h pressure, more preferably 8 l/m 2 /h to 15 l/m 2 /h, pressure 15 to 50 bar, preferably 15 to 40 bar, more preferably 15 to 35 bar, and temperature ≦ It is carried out at 60°C, preferably ≦50°C, ≦40°C, more preferably ≦30°C.
It is also advantageous to protect these concentrates from microbial contamination. This can be achieved, for example, by lowering the pH value and/or by adding suitable preservatives as mentioned above.
Freeze-drying, also referred to as freeze-drying or sublimation drying, is an extremely gentle process, although cost-intensive and relatively complex. Freeze-drying is based on the physical process of sublimation: by this process ice crystals sublimate directly into the gaseous state without the appearance of an intermediate liquid phase. In this case, freeze-drying produces a solid that can be stored well without the addition of preservatives. Freeze-drying procedures can be taken, for example, from GB1447988 and DE19817177.
噴霧乾燥、例えば流動層において、乾燥される材料は気化器によって熱ガス気流に導入され、非常に短時間(数秒から1秒の何分の一か)のうちに微粉末に乾燥される。噴霧乾燥は、任意選択で、マルトデキストリン、シクロデキストリンなどの前述の担体の添加を伴って行われてよい。ここでの利点は、費用効率よく行うことができる確立された方法であることである。より高温、例えば200~400℃、好ましくは250~270℃において、非常に短時間の、例えば数秒、好ましくは3秒未満または1秒未満の暴露のみが必要である。保存剤を添加することなく十分に保存できる固体が、得られる。
セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、好ましくは本発明の方法によって得ることができる。
In spray drying, for example in a fluidized bed, the material to be dried is introduced into a hot gas stream by means of a vaporizer and is dried to a fine powder within a very short time (from a few seconds to a fraction of a second). Spray drying may optionally be carried out with the addition of the aforementioned carriers such as maltodextrins, cyclodextrins, etc. The advantage here is that it is an established method that can be performed cost-effectively. At higher temperatures, such as from 200 to 400°C, preferably from 250 to 270°C, only very short exposures, such as a few seconds, preferably less than 3 seconds or less than 1 second, are required. A solid is obtained which can be stored well without the addition of preservatives.
Yarrow fresh plant juice concentrate can preferably be obtained by the method of the invention.
一実施形態によれば、化粧用組成物、医薬組成物、食品組成物または補助食品が提供される。医薬組成物、食品組成物または補助食品は、それぞれ、本発明のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を含む。化粧用組成物は、本発明のセイヨウノコギリソウフレッシュ植物圧搾汁またはセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を含む。
本発明の濃縮物はヒト用化粧品およびケア、特に皮膚および毛髪のケア、において幅広い範囲の適用を有するが、また、医薬用として、ならびに食品および補助食品においても使用することができる。
化粧用組成物は、特に、皮膚化粧用、毛髪化粧用、皮膚科学的および衛生用組成物であってよい。特に、本発明の濃縮物は、皮膚および/または毛髪化粧品に使用される。
According to one embodiment, a cosmetic composition, a pharmaceutical composition, a food composition or a food supplement is provided. The pharmaceutical composition, food composition or food supplement each comprises the Yarrow fresh plant juice concentrate of the present invention. The cosmetic composition comprises Yarrow fresh plant juice or Yarrow fresh plant juice concentrate of the present invention.
The concentrates of the invention have a wide range of applications in human cosmetics and care, in particular skin and hair care, but can also be used medicinally and in foods and food supplements.
Cosmetic compositions may in particular be dermocosmetic, haircosmetic, dermatological and hygiene compositions. In particular, the concentrates of the invention are used in skin and/or hair cosmetics.
本発明の毛髪または皮膚ケア用組成物または調製物は、好ましくはエマルション、ディスパーション、懸濁液の形態、水性界面活性剤調製物の形態、ミルク、ローション、クリーム、バーム、軟膏、ゲル、顆粒、粉末、例えばリップスティックなどのスティック調製物、フォーム、エアロゾルまたはスプレーであってよい。こうした処方は、局所用調製物に適している。水中油エマルションおよび油中水エマルションまたはマイクロエマルションが、エマルションとして使用され得る。
一般に、毛髪または皮膚化粧用調製物は、皮膚または毛髪への適用のために使用される。「局所用調製物」は、活性成分を、細かく分散させた形態、例えば皮膚から吸収される形態で、皮膚に塗布するのに適した調製物を意味する。適切なものは、例えば、水性および水性アルコール溶液、スプレー、フォーム、フォームエアロゾル、軟膏、水性ゲル、O/W型またはW/O型のエマルション、マイクロエマルションまたは化粧用スティック調製物である。
The hair or skin care compositions or preparations of the invention are preferably in the form of emulsions, dispersions, suspensions, aqueous surfactant preparations, milks, lotions, creams, balms, ointments, gels, granules. , a powder, a stick preparation such as a lipstick, a foam, an aerosol or a spray. Such formulations are suitable for topical preparation. Oil-in-water emulsions and water-in-oil emulsions or microemulsions can be used as emulsions.
Generally, hair or skin cosmetic preparations are used for application to the skin or hair. "Topical preparation" means a preparation suitable for application to the skin, containing the active ingredient in finely dispersed form, eg, in a form that is absorbed through the skin. Suitable are, for example, aqueous and hydroalcoholic solutions, sprays, foams, foam aerosols, ointments, aqueous gels, O/W or W/O emulsions, microemulsions or cosmetic stick preparations.
化粧用組成物は、1つ(またはいくつかの)担体を含んでよい。担体として好ましいのは、水、気体、水ベースの液体、油、ゲル、エマルションまたはマクロエマルション、ディスパーションまたはこれらの混合物である。記述された担体は、良好な皮膚適合性を示す。局所用調製物にとって特に有利なのは、水性ゲル、エマルションまたはマイクロエマルションである。担体はまた、均一相処方の形態またはエマルションの形態であってもよい。エマルションは、水中油、油中水または多相エマルションであってよい。これらのエマルションは、(スプレーまたはエアロゾルとして投与することもできる)流動ローション、クリーミーローション、軽いまたは重いクリームおよびこれらに類するものを含む広範な粘稠性で使用されてよい。他の適切な担体には、無水液体溶媒、例えば油およびアルコール、水ベースの単相液体溶媒(例えば、含水アルコール溶媒系)、無水固体および半固体(例えば、ゲルおよびスティック)および水ベースのゲルおよびフォーム系などが含まれる。本発明の枠組みの範囲内において適切な担体および担体系の例は、例えば、"Sun Products Formulary" Cosmetics & Toiletries, Vol. 105, p. 122-139 (December 1990); "Sun Products Formulary", Cosmetics & Toiletries, Vol. 102, p. 117-136 (March 1987); 米国特許第4960764号,Figueroa et al.;および米国特許第4254105号,Fukuda et al.から採り上げることができる。 Cosmetic compositions may include one (or several) carriers. Preferred carriers are water, gases, water-based liquids, oils, gels, emulsions or macroemulsions, dispersions or mixtures thereof. The described carrier shows good skin compatibility. Particularly advantageous for topical preparations are aqueous gels, emulsions or microemulsions. The carrier may also be in the form of a homogeneous formulation or an emulsion. Emulsions may be oil-in-water, water-in-oil or multiphase emulsions. These emulsions may be used in a wide range of consistencies, including liquid lotions (which may also be administered as sprays or aerosols), creamy lotions, light or heavy creams, and the like. Other suitable carriers include anhydrous liquid solvents such as oils and alcohols, water-based single phase liquid solvents (e.g. hydroalcoholic solvent systems), anhydrous solids and semi-solids (e.g. gels and sticks) and water-based gels. and foam types. Examples of suitable carriers and carrier systems within the framework of the invention are, for example, "Sun Products Formulary" Cosmetics & Toiletries, Vol. 105, p. 122-139 (December 1990); "Sun Products Formulary", Cosmetics & Toiletries, Vol. 102, p. 117-136 (March 1987); US Pat. No. 4,960,764, Figueroa et al. and U.S. Pat. No. 4,254,105, Fukuda et al. It can be picked up from.
本発明の教示はまた、医薬組成物における本明細書に記載の濃縮物の使用をも含む。この医薬組成物は、個体、好ましくは哺乳類、特にヒトの治療のための医薬として使用されてよい。医薬組成物は、通常、本発明の濃縮物および、適切な場合には、1つまたはいくつかの他の活性物質と共に薬学的に許容される賦形剤を含む。 The teachings of the present invention also include the use of the concentrates described herein in pharmaceutical compositions. This pharmaceutical composition may be used as a medicament for the treatment of individuals, preferably mammals, especially humans. Pharmaceutical compositions usually contain a concentrate of the invention and, if appropriate, a pharmaceutically acceptable excipient together with one or several other active substances.
これらの組成物は、例えば、経口でおよび経皮で投与されてよい。適切な医薬用処方の例は、粉末、顆粒、錠剤、トローチ、サシェ、カシェー、糖衣錠、ハードおよびソフトゼラチンカプセルなどのカプセル、半固体投与形態、例えば軟膏、クリーム、ハイドロゲル、ペーストまたはプラスターなど、ならびに液体投与形態、例えば溶液、エマルション、特に水中油エマルション、およびローションなどのサスペンションである。
本発明の組成物の製造において、本発明に従って使用される構成要素または活性成分は、通常、賦形剤で混合されるかまたは希釈される。賦形剤は、濃縮物中に含まれる活性成分のビヒクル、担体または媒体として働く、固体、半固体または液体材料であってよい。活性物質の(本発明に従って同時に含まれる1つまたはいくつかの活性物質の)含有量は、幅広い範囲にわたって変動してよい。
These compositions may be administered, for example, orally and transdermally. Examples of suitable pharmaceutical formulations are powders, granules, tablets, troches, sachets, cachets, dragees, capsules such as hard and soft gelatin capsules, semi-solid dosage forms such as ointments, creams, hydrogels, pastes or plasters, etc. and liquid dosage forms such as solutions, emulsions, especially oil-in-water emulsions, and suspensions such as lotions.
In producing the compositions of the invention, the components or active ingredients used according to the invention are usually mixed or diluted with excipients. Excipients may be solid, semi-solid or liquid materials that serve as vehicles, carriers or mediums for the active ingredient contained in the concentrate. The content of active substances (of one or several active substances included at the same time according to the invention) may vary over a wide range.
適切な賦形剤には、乳糖、ブドウ糖、ショ糖、ソルビトール、マンニトール、デンプン、アカシアガム、リン酸カルシウム、アルギネート、トラガント、ゼラチン、ケイ酸カルシウム、マイクロクリスタリンセルロース、ポリビニルピロリドン、セルロース、水、シロップおよびメチルセルロースが含まれる。さらに、処方は薬学的に許容される担体または一般的な賦形剤、例えば、獣脂、ステアリン酸マグネシウムおよび鉱油などの滑沢剤など;湿潤剤;乳化剤および懸濁化剤;ヒドロキシ安息香酸メチルおよびプロピルなどの保存剤;抗酸化剤;抗刺激剤:キレート化剤;コーティング助剤;エマルション安定化剤;被膜形成剤;ゲル化剤;臭気マスキング剤;香味矯正剤;樹脂;ハイドロコロイド;溶媒;可溶化剤;中和剤;浸透促進剤;顔料;第四級アンモニウム化合物;加脂肪剤および過脂肪剤;軟膏、クリームまたは油性基剤;シリコーン誘導体;延展助剤;安定化剤;殺菌剤;坐剤基剤;バインダー、フィラー、滑沢剤、崩壊剤またはコーティング剤などの錠剤補助剤;噴射剤;乾燥剤;乳白剤;増粘剤;ワックス;可塑剤;ホワイトオイルを含んでよい。この点において設計は、例えば、Fiedler, H. P., Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete, 4th edition, Aulendorf: ECV-Editio-Kantor-Verlag, 1996、またはHager's Handbuch der Pharmazeutischen Praxis, Springer Verlag, Heidelbergに示されるように、当業者の知識に基づく。 Suitable excipients include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. is included. Additionally, the formulation includes pharmaceutically acceptable carriers or common excipients, such as lubricants such as tallow, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; methyl hydroxybenzoate and Preservatives such as propyl; antioxidants; anti-irritants; chelating agents; coating aids; emulsion stabilizers; film-forming agents; gelling agents; odor masking agents; flavor correctors; resins; hydrocolloids; solvents; Solubilizing agents; neutralizing agents; penetration enhancers; pigments; quaternary ammonium compounds; fatliquing and superfatting agents; ointments, creams or oily bases; silicone derivatives; spreading aids; stabilizers; bactericidal agents; Tablet adjuvants such as binders, fillers, lubricants, disintegrants or coating agents; propellants; desiccants; opacifiers; thickeners; waxes; plasticizers; white oils. The design in this respect can be found in, for example, Fiedler, H. P., Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete, 4th edition, Aulendorf: ECV-Editio-Kantor-Verlag, 1996, or Hager's Handbuch der Pharmazeutischen Praxis, Springer Verlag, Heidelberg. As indicated, based on the knowledge of a person skilled in the art.
本発明の枠組みの範囲内で、本発明のフレッシュ植物圧搾汁または濃縮物を組み合わせることまたは本発明に従って、例えば、研磨剤、抗アクネ剤および皮脂減少剤、抗老化剤、抗菌剤、抗セルライト剤、抗フケ剤、抗炎症剤、刺激防止剤、抗刺激剤(抗炎症、刺激抑制および刺激予防剤)、抗微生物剤、抗酸化剤、収斂剤、保存剤、帯電防止剤、バインダー、緩衝剤、担体、キレート化剤、細胞賦活剤、クレンジング剤、ケア剤、脱毛剤、界面活性剤、デオドラントおよび制汗剤、可塑剤、乳化剤、酵素、精油、昆虫忌避剤、繊維、被膜形成剤、定着剤、起泡剤、泡安定化剤、消泡剤、起泡促進剤、殺真菌剤、ゲル化剤およびゲル形成剤、ヘアケア剤、ヘアシェイピング剤、ヘアストレート剤、水分調節剤(保湿、湿潤および/または給湿物質)、浸透圧調節物質、適合溶質、漂白剤、増強剤、染着除去剤、蛍光増白剤、含侵剤、防汚剤、摩擦低減剤、滑沢剤、保湿クリーム、軟膏、濁り剤、可塑剤、乳白剤、艶出し剤、光沢剤、ポリマー、粉末、タンパク質およびタンパク質加水分解物、加脂肪剤、研削剤、皮膚鎮静剤、皮膚クレンジング剤、皮膚ケア剤、好ましくはコレステロールおよび/または脂肪酸および/またはセラミドおよび/または疑似セラミドを含む皮膚修復剤、皮膚ホワイトニング剤、皮膚保護剤、皮膚軟化剤、皮膚冷却剤、好ましくはWO2005/123101に記載の皮膚加温剤、UV吸収剤およびUVフィルター、好ましくはWO2005/123101に記載のもの、ベンジリデン-β-ジカルボニル化合物、α-ベンゾイルケイ皮酸ニトリル、AhR受容体拮抗剤、洗剤、織物柔軟剤、懸濁化剤、皮膚タンニング剤、増粘剤、ビタミン、油、ワックスおよび脂質、リン脂質、脂肪酸(飽和脂肪酸、モノ-またはポリ不飽和脂肪酸、α-ヒドロキシ酸、ポリヒドロキシ脂肪酸)、可塑剤、染料および着色保護剤ならびに顔料、防食剤、芳香剤および香味剤ならびに香料、好ましくはS. Arctander, Perfume and Flavor Chemicals, self-published, Montclair, N.J., 1969およびSurburg, Panten, Common Fragrance and Flavor Materials, 5th Edition, Wiley-VCH, Weinheim 2006に列挙されているもの、界面活性剤、動物抽出物、酵母エキス、藻類または微細藻類の抽出物、電解質、液化剤、有機溶媒、毛髪成長調節剤(毛髪成長促進または毛髪成長抑制)およびシリコーンおよびシリコーン誘導体、好ましくは1つまたはいくつかの皮膚冷却剤および/または1つまたはいくつかのUV吸収剤またはUVフィルターからなる群から選択される、(他の)(活性な)物質とともに使用することは、一般に可能であり、かつ通常は有利である。
したがって、本発明の組成物はまた、通常の添加剤または賦形剤に加えて、(さらに)美容上および/または皮膚科学的におよび/または薬理学的に活性な剤を含んでよい。
Within the framework of the invention, it is possible to combine fresh plant juices or concentrates according to the invention or in accordance with the invention with, for example, abrasives, anti-acne and sebum-reducing agents, anti-aging agents, antibacterial agents, anti-cellulite agents. , anti-dandruff agents, anti-inflammatory agents, anti-irritants, anti-irritants (anti-inflammatory, anti-irritant and anti-irritating agents), anti-microbial agents, antioxidants, astringents, preservatives, antistatic agents, binders, buffers , carriers, chelating agents, cell activators, cleansing agents, care agents, depilatory agents, surfactants, deodorants and antiperspirants, plasticizers, emulsifiers, enzymes, essential oils, insect repellents, fibers, film-forming agents, fixatives foaming agents, foam stabilizers, antifoaming agents, foaming accelerators, fungicides, gelling agents and gel forming agents, hair care agents, hair shaping agents, hair straightening agents, moisture regulators (moisturizing, moisturizing) and/or humectants), osmotic pressure regulators, compatible solutes, bleaching agents, enhancers, stain removers, optical brighteners, impregnators, antifouling agents, friction reducers, lubricants, moisturizing creams. , ointments, clouding agents, plasticizers, opacifiers, polishes, brighteners, polymers, powders, proteins and protein hydrolysates, fatliquors, abrasives, skin soothing agents, skin cleansing agents, skin care agents, preferably is a skin repair agent, skin whitening agent, skin protection agent, emollient, skin cooling agent, preferably a skin warming agent as described in WO 2005/123101, containing cholesterol and/or fatty acid and/or ceramide and/or pseudoceramide; UV absorbers and UV filters, preferably those described in WO 2005/123101, benzylidene-β-dicarbonyl compounds, α-benzoylcinnamic nitrile, AhR receptor antagonists, detergents, fabric softeners, suspending agents, Skin tanning agents, thickeners, vitamins, oils, waxes and lipids, phospholipids, fatty acids (saturated, mono- or polyunsaturated, alpha-hydroxy acids, polyhydroxy fatty acids), plasticizers, dyes and color protectants. and pigments, anticorrosive agents, fragrances and flavors, and fragrances, preferably S. Arctander, Perfume and Flavor Chemicals, self-published, Montclair, NJ, 1969 and Surburg, Panten, Common Fragrance and Flavor Materials, 5th Edition, Wiley- VCH, Weinheim 2006, surfactants, animal extracts, yeast extracts, algae or microalgae extracts, electrolytes, liquefaction agents, organic solvents, hair growth regulators (promoting or inhibiting hair growth) ) and (other) (active) substances selected from the group consisting of silicones and silicone derivatives, preferably one or several skin cooling agents and/or one or several UV absorbers or UV filters. Their use together is generally possible and usually advantageous.
The compositions of the invention may therefore also contain (further) cosmetically and/or dermatologically and/or pharmacologically active agents in addition to the customary additives or excipients.
適切な美容上および/または皮膚科学的に活性な剤は、例えば、着色剤、皮膚および毛髪染色剤、色付け剤、タンニング剤、漂白剤、ケラチン硬化物質、抗微生物剤、光フィルター剤、充血性物質(hyperemising substances)、角質溶解および角質形成物質、抗フケ剤、消炎剤、角質化物質、抗酸化剤またはラジカルスカベンジャーとして活性な物質、皮膚保湿または給湿物質、加脂肪剤、抗紅斑性または抗アレルギー活性剤、18-メチルエイコサン酸などの分枝状脂肪酸、ならびにその混合物である。 Suitable cosmetically and/or dermatologically active agents are, for example, colorants, skin and hair dyes, tinting agents, tanning agents, bleaching agents, keratin-hardening substances, antimicrobial agents, light filtering agents, hyperemic agents. hyperemising substances, keratolytic and keratinogenic substances, antidandruff agents, anti-inflammatory agents, keratinizing substances, substances active as antioxidants or radical scavengers, skin moisturizing or moisturizing substances, fattening agents, antierythematous or antiallergic active agents, branched fatty acids such as 18-methyleicosanoic acid, and mixtures thereof.
UV光線による天然または人工照射なしに皮膚をタンニングするのに適切な人工的皮膚タンニング剤;これらは、例えば、ジヒドロキシアセトン、アロキサンおよびクルミ殻抽出物である。適切なケラチン硬化物質は、通常、制汗剤などに使用されるものなどの剤であり、例えば、硫酸カリウムアルミニウム、クロルヒドロキシアルミニウム、乳酸アルミニウムなどである。 Artificial skin tanning agents suitable for tanning the skin without natural or artificial irradiation with UV light; these are, for example, dihydroxyacetone, alloxan and walnut shell extract. Suitable keratin-hardening substances are agents such as those commonly used in antiperspirants, such as potassium aluminum sulphate, aluminum chlorohydroxyl, aluminum lactate, and the like.
微生物の増殖を阻止または抑制するために使用される抗微生物剤。したがって抗微生物剤は、保存剤としておよび防臭物質として働き、身体の臭気の発生または強度を低減する。抗微生物剤には、例えば、当業者に公知の一般的な保存剤、例えばp-ヒドロキシ安息香酸エステル、イミダゾリジニル尿素、ホルムアルデヒド、ソルビン酸、安息香酸、サリチル酸、などが含まれる。こうした防臭物質は、例えば、リシノール酸亜鉛、トリクロサン、ウンデシレン酸アルキロールアミド、クエン酸トリエチルエステル、クロルヘキシジンなどである。 Antimicrobial agents used to prevent or inhibit the growth of microorganisms. Antimicrobial agents therefore act as preservatives and as deodorants, reducing the production or intensity of body odors. Antimicrobial agents include, for example, common preservatives known to those skilled in the art, such as p-hydroxybenzoic acid esters, imidazolidinyl ureas, formaldehyde, sorbic acid, benzoic acid, salicylic acid, and the like. Such deodorizing substances are, for example, zinc ricinoleate, triclosan, undecylenic acid alkylolamide, citric acid triethyl ester, chlorhexidine, and the like.
当業者は、毛髪化粧用調製物および皮膚化粧用調製物の製造に適切な賦形剤および添加剤をよく知っており、化粧品のマニュアル、例えばSchrader, Grundlagen und Rezepturen der Kosmetika, Huthig Verlag, Heidelberg, 1989, ISBN 3-7785-1491-1、から採り上げることができる。賦形剤および添加剤は、好ましくは化粧品および/または薬学的に許容される賦形剤である。薬学的に許容されるのは、製薬、食品技術、および関連分野において適用可能であることが知られている賦形剤、特に関連の薬局方(例えば、DAB、Ph. Eur.、BP、NF)に収載されている賦形剤、ならびにその特性が生理学的適用と相反しないその他の賦形剤である。 The person skilled in the art is familiar with excipients and additives suitable for the production of hair and skin cosmetic preparations, and is familiar with the excipients and additives suitable for the production of hair and skin cosmetic preparations, and is familiar with cosmetic manuals, such as Schrader, Grundlagen und Rezepturen der Kosmetika, Huthig Verlag, Heidelberg, 1989, ISBN 3-7785-1491-1. Excipients and additives are preferably cosmetically and/or pharmaceutically acceptable excipients. Pharmaceutically acceptable are excipients known to be applicable in pharmaceuticals, food technology and related fields, especially those in the relevant pharmacopeias (e.g. DAB, Ph. Eur., BP, NF). ), as well as other excipients whose properties are compatible with physiological applications.
適切な賦形剤は、滑沢剤、湿潤剤、乳化および懸濁化剤、保存剤、抗酸化剤、抗刺激剤、キレート化剤、エマルション安定化剤、被膜形成剤、ゲル化剤、臭気マスキング剤、ハイドロコロイド、溶媒、可溶化剤、中和剤、浸透促進剤、顔料、第四級アンモニウム化合物、加脂肪剤および過脂肪剤、軟膏、クリームまたは油性基剤、シリコーン誘導体、安定化剤、殺菌剤、噴射剤、乾燥剤、乳白剤、増粘剤、ワックス、可塑剤およびホワイトオイルであってよい。
さらなる適切な添加剤は、香油、ヘアポリマー、毛髪および皮膚コンディショナー、グラフトポリマー、水溶性または分散性シリコーン含有ポリマー、光防御剤、漂白剤、ケア剤、染色剤、色付け剤、タンニング剤、染料、粘稠性向上剤、湿潤剤、加脂肪剤、コラーゲン、タンパク質加水分解物、脂質、抗酸化剤、消泡剤、帯電防止剤、エモリエント剤、可塑剤、過酸化物分解剤から選択される。
適切な賦形剤および添加剤の例として、抗酸化剤、過酸化物分解剤、増粘剤および上述の保存剤を挙げることができる。
Suitable excipients include lubricants, wetting agents, emulsifying and suspending agents, preservatives, antioxidants, anti-irritants, chelating agents, emulsion stabilizers, film-forming agents, gelling agents, odor Masking agents, hydrocolloids, solvents, solubilizers, neutralizing agents, penetration enhancers, pigments, quaternary ammonium compounds, fatliquing and superfatting agents, ointments, creams or oil bases, silicone derivatives, stabilizers, They may be disinfectants, propellants, desiccants, opacifiers, thickeners, waxes, plasticizers and white oils.
Further suitable additives are perfume oils, hair polymers, hair and skin conditioners, graft polymers, water-soluble or dispersible silicone-containing polymers, photoprotectants, bleaching agents, care agents, dyes, tinting agents, tanning agents, dyes, selected from viscosity improvers, humectants, fatliquors, collagen, protein hydrolysates, lipids, antioxidants, defoamers, antistatic agents, emollients, plasticizers, peroxide decomposers.
As examples of suitable excipients and additives, mention may be made of antioxidants, peroxide decomposers, thickeners and the preservatives mentioned above.
過酸化物分解剤は、過酸化物、特に脂質過酸化物を化学的に分解する化合物である。例には、ピリジン-2-チオール-3-カルボン酸、2-メトキシ-ピリミジノールカルボン酸、2-メトキシ-ピリジンカルボン酸、2-ジメチルアミノ-ピリミジノールカルボン酸、2-ジメチルアミノ-ピリジンカルボン酸が含まれる。
増粘剤の例は、架橋ポリアクリル酸およびそれらの誘導体、キサンタンガムなどの多糖およびそれらの誘導体、アガーアガー、アルギネートまたはチロース、セルロース誘導体、例えばカルボキシメチルセルロースまたはヒドロキシカルボキシメチルセルロース、脂肪アルコール、モノグリセリドおよび脂肪酸、ポリビニルアルコールおよびポリビニルピロリドンである。特に、非イオン性増粘剤が使用される。
Peroxide decomposers are compounds that chemically decompose peroxides, especially lipid peroxides. Examples include pyridine-2-thiol-3-carboxylic acid, 2-methoxy-pyrimidinolcarboxylic acid, 2-methoxy-pyridinecarboxylic acid, 2-dimethylamino-pyrimidinolcarboxylic acid, 2-dimethylamino-pyridine Contains carboxylic acid.
Examples of thickeners are crosslinked polyacrylic acids and their derivatives, polysaccharides and their derivatives such as xanthan gum, agar agar, alginates or tylose, cellulose derivatives such as carboxymethylcellulose or hydroxycarboxymethylcellulose, fatty alcohols, monoglycerides and fatty acids, polyvinyl alcohol and polyvinylpyrrolidone. In particular, nonionic thickeners are used.
保存剤に加え、他の細菌抑制剤もまた本発明の組成物に使用および配合することができる。有利な物質は、例えば、2,4,4’-トリクロロ-2’-ヒドロキシジフェニルエーテル(イルガサン)、1,6-ジ-(4-クロロフェニルビグアニド)-ヘキサン(クロルヘキシジン)、3,4,4’-トリクロロカルバニリド、第四級アンモニウム化合物、クローブ油、ミント油、タイム油、クエン酸トリエチル、ファルネソール(3,7,11-トリメチル-2,6,10-ドデカトリエン-1-オール)ならびにDE3740186、DE3938140、DE4204321、DE4229707、DE4309372、DE4411664、DE19541967、DE19543695、DE19543696、DE19547160、DE19502108、DE19602110、DE19602111、DE19631003、DE19631004およびDE19634019ならびにDE4229737、DE4237081、DE4324219、DE4429467、DE4423410およびDE19516705に記載の剤または剤の組合せである。炭酸水素ナトリウムが有利に使用することができる。抗菌ポリペプチドも使用することができる。 In addition to preservatives, other antibacterial agents can also be used and incorporated into the compositions of the present invention. Preferred substances are, for example, 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Irgasan), 1,6-di-(4-chlorophenylbiguanide)-hexane (chlorhexidine), 3,4,4'- Trichlorocarbanilide, quaternary ammonium compounds, clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7,11-trimethyl-2,6,10-dodecatrien-1-ol) and DE3740186, DE3938140, DE4204321, DE4229707, DE4309372, DE4411664, DE19541967, DE19543695, DE19543696, DE19547160, DE19502108, DE19602110, DE19602 111, DE19631003, DE19631004 and DE19634019 and the agents or combinations of agents described in DE4229737, DE4237081, DE4324219, DE4429467, DE4423410 and DE19516705. be. Sodium bicarbonate can advantageously be used. Antimicrobial polypeptides can also be used.
光フィルター剤もまた含まれてよい。これらの剤は、UV-Bおよび/またはUV-A範囲のUV光線を吸収する。適切なUVフィルターは、例えば、アリール基がそれぞれ、好ましくはヒドロキシ、アルコキシ、特に、メトキシ、アルコキシカルボニル、特にメトキシカルボニルおよびエトキシカルボニル、ならびにこれらの混合物から選択される少なくとも1つの置換基をもつことができる、2,4,6-トリアリール-1,3,5-トリアジンである。同様に適切なのは、p-アミノ安息香酸エステル、ケイ皮酸エステル、ベンゾフェノン、カンフル誘導体ならびにUV光線を遮蔽する顔料、例えば二酸化チタン、タルカムおよび酸化亜鉛などの顔料である。
いかなるUV-AおよびUV-Bフィルター物質も、UVフィルター物質とみなすことができる。言及できる例は:
Light filtering agents may also be included. These agents absorb UV radiation in the UV-B and/or UV-A range. Suitable UV filters are suitable, for example, in which the aryl groups each carry at least one substituent, preferably selected from hydroxy, alkoxy, in particular methoxy, alkoxycarbonyl, in particular methoxycarbonyl and ethoxycarbonyl, and mixtures thereof. 2,4,6-triaryl-1,3,5-triazine. Also suitable are p-aminobenzoic acid esters, cinnamic acid esters, benzophenones, camphor derivatives and pigments that screen UV radiation, such as titanium dioxide, talcum and zinc oxide.
Any UV-A and UV-B filter material can be considered a UV filter material. Examples that can be mentioned are:
本発明の化粧用および皮膚科学的調製物はまた、有利には、例えば、水に不溶または難溶で、UV光線を遮蔽する、亜鉛酸化物(ZnO)、チタン酸化物(TiO2)、鉄酸化物(例えば、Fe2O3)、ジルコニウム酸化物(ZrO2)、ケイ素酸化物(SiO2)マンガン酸化物(例えば、MnO)、アルミニウム酸化物(AI2O3)セリウム酸化物(例えば、Ce2O3)、当該金属の混合酸化物およびこうした酸化物の混合物の群から選択される、金属酸化物ベースの無機顔料および/または他の金属化合物を含んでよい。
適切な充血性物質もまた、化粧用または医薬組成物に含まれてよい。充血性物質は、皮膚の血液循環を刺激する。例は、マウンテンパイン抽出物、ラベンダー抽出物、ローズマリー抽出物、ジュニパーベリー抽出物、マロニエ抽出物、バーチ葉抽出物、ヘイフラワー抽出物、酢酸エチル、カンフル、メントール、ペパーミント油、ローズマリー抽出物、ユーカリ油、などの精油である。
角質溶解および角質形成物質もまた含まれてよい。こうした物質の例には、サリチル酸、チオグリコール酸カルシウム、チオグリコール酸およびそれらの塩、イオウなどが含まれる。適切な抗フケ剤はイオウ、イオウポリエチレングリコール、ソルビタンモノオレエート、イオウリシノールポリエトキシレート、亜鉛ピリチオン、アルミニウムピリチオンなどである。
皮膚刺激を和らげる適切な消炎剤は、例えば、アラントイン、ビザボロール、ドラゴサントール(dragosantol)、カモミール抽出物、パンテノールなどである。
The cosmetic and dermatological preparations of the invention may also advantageously contain, for example, zinc oxide (ZnO), titanium oxide (TiO 2 ), iron oxides (e.g. Fe 2 O 3 ), zirconium oxide (ZrO 2 ), silicon oxide (SiO 2 ), manganese oxide (e.g. MnO), aluminum oxide (AI 2 O 3 ), cerium oxide (e.g. Ce 2 O 3 ), mixed oxides of such metals and mixtures of such oxides, inorganic pigments and/or other metal compounds based on metal oxides may be included.
Suitable hyperemic substances may also be included in the cosmetic or pharmaceutical composition. Hyperemic substances stimulate blood circulation in the skin. Examples are mountain pine extract, lavender extract, rosemary extract, juniper berry extract, horse chestnut extract, birch leaf extract, hayflower extract, ethyl acetate, camphor, menthol, peppermint oil, rosemary extract. , eucalyptus oil, etc.
Keratolytic and keratinogenic substances may also be included. Examples of such substances include salicylic acid, calcium thioglycolate, thioglycolic acid and their salts, sulfur, and the like. Suitable anti-dandruff agents include sulfur, sulfur polyethylene glycol, sorbitan monooleate, sulfur uricinol polyethoxylate, zinc pyrithione, aluminum pyrithione, and the like.
Suitable anti-inflammatory agents to soothe skin irritation are, for example, allantoin, bizabolol, dragosantol, chamomile extract, panthenol, and the like.
化粧品または薬学的に許容される、カチオン性、両性および中性ポリマーなどのポリマー。適切なポリマーは、例えば、INCIによる名称polyquaternium(ポリクオタニウム)を有するカチオン性ポリマーであり、例えば、ビニルピロリドン/N-ビニルイミダゾリウム塩のコポリマー(Luviquat FC、Luviquat HM、Luviquat MS、Luviquat Care)、硫酸ジエチルで四級化されたN-ビニルピロリドン/ジメチルアミノエチルメタクリレートのコポリマー(Luviquat PQ 11)、N-ビニルカプロラクタム/N-ビニルピロリドン/N-ビニルイミダゾリウム塩のコポリマー(Luviquat E Hold)、カチオン性セルロース誘導体(ポリクオタニウム-4および-10)、アクリルアミドコポリマー(ポリクオタニウム-7)およびキトサンである。 Cosmetic or pharmaceutically acceptable polymers such as cationic, amphoteric and neutral polymers. Suitable polymers are, for example, cationic polymers with the name polyquaternium according to INCI, such as copolymers of vinylpyrrolidone/N-vinylimidazolium salts (Luviquat FC, Luviquat HM, Luviquat MS, Luviquat C are), sulfuric acid Copolymer of N-vinylpyrrolidone/dimethylaminoethyl methacrylate quaternized with diethyl (Luviquat PQ 11), copolymer of N-vinylcaprolactam/N-vinylpyrrolidone/N-vinylimidazolium salt (Luviquat E Hold), cationic These are cellulose derivatives (polyquaternium-4 and -10), acrylamide copolymers (polyquaternium-7) and chitosan.
適切なカチオン性(四級化)ポリマーはまた、メルカット(merquat)(塩化ジメチルジアリルアンモニウムをベースとするポリマー)、ガフカット(gafquat)(ポリビニルピロリドンと第四級アンモニウム化合物との反応により形成される第四級ポリマー)、ポリマーJR(polymer JR)(カチオン基をもつヒドロキシエチエルセルロース)および植物ベースのカチオン性ポリマー、例えば、Rhodia社のJaguarブランドなどのグアーポリマー、である。 Suitable cationic (quaternized) polymers are also merquat (a polymer based on dimethyldiallylammonium chloride), gafquat (a polymer formed by the reaction of polyvinylpyrrolidone with a quaternary ammonium compound), polymer JR (hydroxyethylcellulose with cationic groups) and plant-based cationic polymers, such as guar polymers such as the Jaguar brand from Rhodia.
その他の適切なポリマーはまた、ポリビニルピロリドン、N-ビニルピロリドンおよび酢酸ビニルおよび/またはプロピオン酸ビニルのコポリマー、ポリシロキサン、ポリビニルカプロラクタム、およびN-ビニルピロリドンとの他のコポリマー、ポリエチレンイミンおよびそれらの塩、ポリビニルアミンおよびそれらの塩、セルロース誘導体、ポリアスパラギン酸塩およびそれらの誘導体、などの中性ポリマーである。これらは例えば、Luviflex(登録商標)Swing(ポリ酢酸ビニルとポリエチレングリコールの部分的に鹸化されたコポリマー、BASF社)を含む。
適切なポリマーはまた、非イオン性、水溶性または水分散性ポリマーまたはオリゴマー、例えば、ポリビニルカプロラクタム、例えばLuviskol(登録商標)Plus(BASF)、またはポリビニルピロリドンおよびそれらのコポリマー、特に酢酸ビニルなどのビニルエステルとのコポリマー、例えば、B.Luviskol(登録商標)VA37(BASF)、ポリアミド、例えばイタコン酸および脂肪族ジアミンベースのもの、例えばDE-A-4333238に記載のようなものなどである。
Other suitable polymers are also polyvinylpyrrolidone, copolymers of N-vinylpyrrolidone and vinyl acetate and/or vinyl propionate, polysiloxanes, polyvinylcaprolactam and other copolymers with N-vinylpyrrolidone, polyethyleneimine and their salts. , polyvinylamine and their salts, cellulose derivatives, polyaspartates and their derivatives, and other neutral polymers. These include, for example, Luviflex® Swing (a partially saponified copolymer of polyvinyl acetate and polyethylene glycol, BASF).
Suitable polymers are also non-ionic, water-soluble or water-dispersible polymers or oligomers, for example polyvinylcaprolactam, such as Luviskol® Plus (BASF), or polyvinylpyrrolidone and their copolymers, especially vinyl acetate, such as Copolymers with esters, such as B. Luviskol® VA37 (BASF), polyamides such as those based on itaconic acid and aliphatic diamines, such as those described in DE-A-4333238.
適切なポリマーはまた、両性または双極性ポリマー、例えばAmphomer(National Starch)の名称で入手可能なオクチルアクリルアミド/メチルメタクリレート/tert-ブチルアミノエチルメタクリレート-ヒドロキシプロピル-メタクリレートコポリマーなど、ならびに、例えばDE3929973、DE2150557、DE2817369およびDE3708451に開示のものなどの双極性ポリマーである。アクリルアミドプロピルトリメチルアンモニウムクロリド/アクリル酸またはメタクリル酸コポリマーおよびそれらのアルカリおよびアンモニウム塩は、好ましい双極性ポリマーである。さらなる適切な双極性ポリマーは、Amersette(AMERCHOL)の名称で市販されているメタクロイルエチルベタイン/メタクリレートコポリマー、ならびにヒドロキシエチルメタクリレート、メチルメタクリレート、N,N-ジメチルアミノエチルメタクリレートおよびアクリル酸のコポリマー(Jordapon (D))である。適切なポリマーはまた、非イオン性、シロキサン含有、水溶性または水分散性ポリマー、例えば、Tegopren(登録商標)(Goldschmidt社)またはBesi(Wacker社)などのポリエーテルシロキサン、である。
本発明のさらなる課題は、本発明の濃縮物を含む食品または補助食品に関する。
Suitable polymers are also amphoteric or dipolar polymers, such as octylacrylamide/methyl methacrylate/tert-butylaminoethyl methacrylate-hydroxypropyl-methacrylate copolymers available under the name Amphomer (National Starch), and for example DE 3929973, DE 2150557 , DE2817369 and DE3708451. Acrylamidopropyltrimethylammonium chloride/acrylic acid or methacrylic acid copolymers and their alkali and ammonium salts are preferred dipolar polymers. Further suitable dipolar polymers are the methacroylethyl betaine/methacrylate copolymers sold under the name Amersette (AMERCHOL) and the copolymers of hydroxyethyl methacrylate, methyl methacrylate, N,N-dimethylaminoethyl methacrylate and acrylic acid (Jordapon). (D)). Suitable polymers are also non-ionic, siloxane-containing, water-soluble or water-dispersible polymers, for example polyether siloxanes such as Tegopren® (Goldschmidt) or Besi (Wacker).
A further object of the invention relates to foods or food supplements comprising the concentrates of the invention.
調製される製品は、それらに濃縮物が直接添加される食品である限りにおいて、何らかの種類の食料品である。例えば、ベーカリー製品、アルコールまたはノンアルコール飲料、果実ベースのレモネード、(炭酸を含む)アイソトニック飲料、(炭酸を含む)ソフトドリンク、ネクター、スプリッツァー、果実および野菜ジュース、果実または野菜ジュース調製物および乳製品を挙げることができる。好ましくは、これらは調製する間に加熱する必要がない食料品である。
製品が補助食品である場合、製品は一般に、純粋な包装材料以外に、いかなる他の添加物をも伴うことなく使用される。マクロカプセルまたはマイクロカプセルは、好ましい適用形態である。マクロカプセルは好ましくは、ゼラチンからなるか、あるいは多糖またはデキストリンをベースとして含む噴霧乾燥製品である。
一実施形態によれば、化粧用組成物または医薬組成物は、0.01~10質量%の皮膚鎮静剤および/または抗酸化剤をさらに含む。
局所用組成物に適切な皮膚鎮静剤またはエモリエント剤の例には、ビサボロール、アラントイン、メントール、ショ糖、センテラ抽出物、カンゾウ抽出物、ファルネソール、ルスカス抽出物、ゼニアオイ抽出物、ジャスミン抽出物、ローズマリー酸およびローズマリー酸を含む植物抽出物、カラスムギ抽出物、ショウガ抽出物、[6]-パラドール、ハマメリス抽出物、カレンデュラ抽出物、アルニカ抽出物、エキナセア抽出物、水添ポリイソブテン、C12-C15安息香酸アルコール、ミリスチン酸イソプロピル、鉱油、ラノリンおよびラノリン誘導体、例えばココナツ油などのトリグリセリド、セトステアリルアルコール、セチルアルコール、パルミチン酸イソプロピル、カプリル酸/カプリン酸トリグリセリド、PPG-2ミリスチルエーテルプロピオネート、ジメチコン、メチコン、ワセリンおよび当業者に周知の他の皮膚鎮静剤が含まれる。
The products prepared are food products of any kind insofar as they are food products to which the concentrate is directly added. For example, bakery products, alcoholic or non-alcoholic beverages, fruit-based lemonades, isotonic (carbonated) drinks, soft drinks (carbonated), nectars, spritzers, fruit and vegetable juices, fruit or vegetable juice preparations and dairy products. can be mentioned. Preferably, these are food products that do not require heating during preparation.
If the product is a food supplement, it is generally used without any other additives other than the pure packaging material. Macrocapsules or microcapsules are a preferred application form. Macrocapsules are preferably spray-dried products consisting of gelatin or containing polysaccharides or dextrins as a base.
According to one embodiment, the cosmetic or pharmaceutical composition further comprises 0.01-10% by weight of skin soothing agents and/or antioxidants.
Examples of suitable skin soothing or emollient agents for topical compositions include bisabolol, allantoin, menthol, sucrose, centella extract, licorice extract, farnesol, ruscus extract, mallow extract, jasmine extract, rose Plant extracts containing maricic acid and rosemaric acid, oat extract, ginger extract, [6]-paradol, Hamamelis extract, calendula extract, arnica extract, echinacea extract, hydrogenated polyisobutene, C12-C15 benzoin Acid alcohols, isopropyl myristate, mineral oil, lanolin and lanolin derivatives, triglycerides such as coconut oil, cetostearyl alcohol, cetyl alcohol, isopropyl palmitate, caprylic/capric triglyceride, PPG-2 myristyl ether propionate, dimethicone, Includes methicone, petrolatum and other skin soothing agents well known to those skilled in the art.
抗酸化剤は好ましくは、アミノ酸(例えばグリシン、ヒスチジン、チロシン、トリプトファン)およびその誘導体、イミダゾール(例えばウロカニン酸)およびその誘導体、D,L-カルノシン、D-カルノシン、L-カルノシンなどのペプチドおよびその誘導体(例えば、アンセリン)、カロテノイド、カロテン(例えばβ-カロテン、リコペン)およびその誘導体、クロロゲン酸およびその誘導体、リポ酸およびその誘導体(例えば、ジヒドロリポ酸)、オーロチオグルコース、プロピルチオウラシルおよび他のチオール(例えばチオロドキシン、グルタチオン、システイン、シスチン、シスタミンおよびこれらのグリコシル、N-アセチル、メチル、エチル、プロピル、アミル、ブチルおよびラウリル、パルミトイル、オレイル、y-リノレイル、コレステリルおよびグリセリルエステル)およびこれらの塩、ジラウリルチオジプロピオネート、ジステアリルチオジプロピオネート、チオジプロピオン酸およびその誘導体(エステル、エーテル、ペプチド、脂質、ヌクレオチド、ヌクレオシドおよび塩)およびスルホキシイミン化合物(例えばブチオニンスルホキシイミン、ホモシステインスルホキシイミン、ブチオニンスルホン、ペンタ-、ヘキサ-、ヘプタチオニンスルホキシイミン)、特に非常に低い適合性用量(例えばpmolからμmol/kgの範囲)において、さらなる(金属)-キレート剤(例えばd-ヒドロキシ脂肪酸、パルミチン酸、フィチン酸、ラクトフェリン)、o-ヒドロキシ酸(例えばクエン酸、乳酸、リンゴ酸)、フミン酸、胆汁酸、胆汁抽出物、ビリルビン、ビリベルジン、EDTAおよびその誘導体、不飽和脂肪酸およびその誘導体(例えばv-リノレン酸、リノール酸、オレイン酸)、葉酸およびその誘導体、ユビキノンおよびユビキノール(ubiquinolv)およびその誘導体、ビタミンCおよびその誘導体(例えばアスコルビン酸ナトリウム、パルミチン酸アスコルビル、リン酸アスコルビルMg、酢酸アスコルビル)、トコフェロールおよびその誘導体(例えばビタミンEアセテート、トコトリエノール)、ビタミンAおよび誘導体(ビタミンAパルミテート)ならびに安息香樹脂のコニフェリルベンゾエート、ルチン酸およびその誘導体、o-グリコシルルチン、フェルラ酸、フルフリリデングルシトール、カルノシン、ブチルヒドロキシトルエン、ブチルヒドロキシアニソール、ノルジヒドログアイアク樹脂酸、ノルジヒドログアイアレチン酸、トリヒドロキシブチロフェノン、[6]-パラドール、4-ヒドロキシアセトフェノン、尿酸およびその誘導体、マンノースおよびその誘導体、亜鉛およびその誘導体(例えばZnO、ZnSO4)、セレンおよびその誘導体(例えばセレノメチオニン)、スチルベンおよびその誘導体(例えばスチルベンオキシド、trans-スチルベンオキシド)から選択される。
一実施形態によれば、セイヨウノコギリソウの使用は、皮膚細胞における熱ショックタンパク質(HSP)および/または抗菌ペプチド(AMP)の発現を刺激するために提供される。
Antioxidants are preferably amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D,L-carnosine, D-carnosine, L-carnosine and their derivatives. derivatives (e.g. anserine), carotenoids, carotenes (e.g. β-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (e.g. dihydrolipoic acid), aurothioglucose, propylthiouracil and others. Thiols (e.g. thiorodoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, y-linoleyl, cholesteryl and glyceryl esters) and their salts , dilaurylthiodipropionate, distearylthiodipropionate, thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (e.g. buthionine sulfoximine, homocysteine). sulfoximine, buthionine sulfone, penta-, hexa-, heptathionine sulfoximine), especially at very low compatible doses (e.g. in the pmol to μmol/kg range), further (metal)-chelating agents (e.g. d - hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), o-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acids, bile acids, bile extracts, bilirubin, biliverdin, EDTA and its derivatives, unsaturated fatty acids and its derivatives (e.g. v-linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol (ubiquinolv) and its derivatives, vitamin C and its derivatives (e.g. sodium ascorbate, ascorbyl palmitate, ascorbyl phosphate). Mg, ascorbyl acetate), tocopherols and their derivatives (e.g. vitamin E acetate, tocotrienols), vitamin A and derivatives (vitamin A palmitate) and coniferyl benzoate of benzoic resin, rutic acid and its derivatives, o-glycosylrutin, ferulic acid, Furfurylidenglucitol, carnosine, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiac resin acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, [6]-paradol, 4-hydroxyacetophenone, uric acid and its derivatives, Selected from mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnSO 4 ), selenium and its derivatives (eg selenomethionine), stilbene and its derivatives (eg stilbene oxide, trans-stilbene oxide).
According to one embodiment, the use of Yarrow is provided for stimulating the expression of heat shock proteins (HSPs) and/or antimicrobial peptides (AMPs) in skin cells.
ヒト皮膚は境界器官であり、とりわけ環境的影響に対する防御をもたらす。ヒト皮膚は常に、数多くの潜在的に危険な微生物に暴露されている。微生物からのこの脅威にもかかわらず、皮膚は感染症に対してきわめて抵抗性である。この10年間に行われたいくつかの研究は、抗菌ペプチドおよびタンパク質(AMP)の産生に基づく皮膚における化学的防御系を示している。AMPは、自然免疫の主要なエフェクター系を構成する多様な群の低分子(12~100のアミノ酸残基)を表す。これらは、病原体に対する防御の最前線を提供する。ハザードに応答して生成されたAMPは、幅広い有効抗菌活性スペクトルにより、細菌、真菌、ウイルスまたは原生動物などの広範な微生物に対して迅速に備えることができる。AMPは、皮膚、眼、耳、口、気道、肺、腸、および尿路などの種々の暴露された組織または表面において認められている。ヒト皮膚において、AMPは、常在皮膚細胞によって構造的にあるいは浸潤する免疫細胞によってあるいは感染、外傷、創傷治癒または慢性炎症などのリスクに応答して産生され得る。AMPは、ヒト皮膚において主としてケラチノサイト、好中球、皮脂腺細胞または汗腺によって産生される。ヒト皮膚のいくつかの疾患において、疾患の重症度とAMP産生のレベルとの間には相互相関がある。アトピー性皮膚炎患者における皮膚損傷は、デフェンシンおよびカテリシジンLL-37の低減を示している。AMPレベルの増加はまた、熱傷および慢性創傷にも関連する。対照的に、AMPの過剰発現は、乾癬、酒さ、および重複感染に至ることは稀な炎症性皮膚感染症の患者において見られるように、皮膚感染症に対する防御増大につながることがある。αおよびβファミリーを含むデフェンシンは、哺乳類において最大かつ最も研究されているAMPファミリーの一つである。これらは、種々の皮膚および骨髄由来細胞によって産生され、グラム陽性菌およびグラム陰性菌、ウイルス、真菌およびいくつかの原生動物に対する広範な抗菌活性スペクトルを発揮し、かつ自然免疫系の重要な構成要素である。βデフェンシンは、皮膚、胃腸管、尿路、および気道を含む、上皮表面を防御する抗菌活性を有するカチオン性ペプチドである。ヒトβ-デフェンシン1ペプチド(hBD-1)は、DEFB1座位によってコード化され、グラム陽性菌およびグラム陰性菌に対して活性である。ジスルフィド架橋の還元後に、hBD-1は、日和見病原性真菌カンジダ・アルビカンス(Candida albicans)に対して有効なAMPになる。黄色ブドウ球菌(S.aureus)および大腸菌(E.coli)に対して、LL-37またはリゾチームと相乗効果を示す。 Human skin is a boundary organ, providing protection against environmental influences, among other things. Human skin is constantly exposed to numerous potentially dangerous microorganisms. Despite this threat from microorganisms, the skin is extremely resistant to infection. Several studies conducted in the last decade have demonstrated a chemical defense system in the skin based on the production of antimicrobial peptides and proteins (AMPs). AMPs represent a diverse group of small molecules (12-100 amino acid residues) that constitute a major effector system of innate immunity. These provide the first line of defense against pathogens. AMPs produced in response to a hazard can be quickly primed against a wide range of microorganisms, such as bacteria, fungi, viruses or protozoa, with a broad spectrum of effective antimicrobial activity. AMP is found in a variety of exposed tissues or surfaces such as the skin, eyes, ears, mouth, respiratory tract, lungs, intestines, and urinary tract. In human skin, AMP can be produced structurally by resident skin cells, by infiltrating immune cells or in response to risks such as infection, trauma, wound healing or chronic inflammation. AMP is produced in human skin primarily by keratinocytes, neutrophils, sebaceous gland cells or sweat glands. In several diseases of human skin, there is a correlation between disease severity and the level of AMP production. Skin lesions in atopic dermatitis patients show reduced defensin and cathelicidin LL-37. Increased AMP levels are also associated with burns and chronic wounds. In contrast, overexpression of AMP can lead to increased protection against skin infections, as seen in patients with psoriasis, rosacea, and inflammatory skin infections that rarely lead to superinfections. Defensins, including the α and β families, are one of the largest and most studied AMP families in mammals. They are produced by a variety of skin- and bone marrow-derived cells, exhibit a broad spectrum of antimicrobial activity against Gram-positive and Gram-negative bacteria, viruses, fungi and some protozoa, and are important components of the innate immune system. It is. Beta-defensins are cationic peptides with antimicrobial activity that protect epithelial surfaces, including the skin, gastrointestinal tract, urinary tract, and respiratory tract. Human β-defensin 1 peptide (hBD-1) is encoded by the DEFB1 locus and is active against Gram-positive and Gram-negative bacteria. After reduction of the disulfide bridges, hBD-1 becomes an effective AMP against the opportunistic pathogenic fungus Candida albicans. Shows synergistic effects with LL-37 or lysozyme against S. aureus and E. coli.
S100タンパク質は、2つのカルシウム結合EFハンドモチーフを特徴とする低分子量カチオン性タンパク質である。S100は、例えば、カルシウム依存性細胞シグナル伝達、細胞増殖、および微生物に対する防御などの、多数の細胞プロセスに関与する。S100カルシウム結合タンパク質A8(S100A8)は、ヒトにおいてS100A8遺伝子によってコード化されるタンパク質である。S100A8(カルグラニュリンA)およびS100A9(カルグラニュリンB)は、表皮ケラチノサイトにおいて、カルプロテクチンとしても知られる抗菌ヘテロ二量体複合体を形成する。S100A8/S100A9複合体はまた、例えば、大腸菌、クレブシエラ属菌(Klebsiella spp.)、黄色ブドウ球菌、表皮ブドウ球菌(S.epidermis)、カプノサイトファガ・スプチゲナ(Capnocytophaga sputigena)およびボレリア・ブルグドルフェリ(Borrelia burgdorferi)などの細菌に対する抗菌活性ならびに真菌カンジダ・アルビカンスに対する抗真菌活性を有することが示されている。 The S100 protein is a low molecular weight cationic protein characterized by two calcium-binding EF hand motifs. S100 is involved in numerous cellular processes, such as calcium-dependent cell signaling, cell proliferation, and defense against microorganisms. S100 calcium binding protein A8 (S100A8) is a protein encoded by the S100A8 gene in humans. S100A8 (calgranulin A) and S100A9 (calgranulin B) form an antimicrobial heterodimeric complex, also known as calprotectin, in epidermal keratinocytes. The S100A8/S100A9 complex can also be used for, for example, E. coli, Klebsiella spp., Staphylococcus aureus, S. epidermis, Capnocytophaga sputigena, and Borrelia burgdorferi. It has been shown to have antibacterial activity against bacteria such as Borrelia burgdorferi as well as antifungal activity against the fungus Candida albicans.
熱ショックタンパク質(HSP)は、細胞死を防止する分子シャペロンである。生物および細胞は、HSPを選択的に上方制御することによって、環境的、代謝的および病態生理学的ストレスなどの種々のストレス状態に反応する。HSPは、熱ショック後(通常、常温から3~5℃高い温度で、1時間以上)にその発現が増大することによって確認される。HSPが細胞を熱ダメージから守るという推定は、以下の事実によって裏付けられる:1)HSP発現は、熱耐性(熱死抵抗性)の発現および低下と正確に並行して起こる;2)HSPの変異または不活性化は高温で生き延びるという細胞の能力を損なう;3)HSPの過剰発現は、高温に耐えるという細胞の能力をしばしば高めることができる。ケイ皮酸誘導体とりわけクロロゲン酸による、ヒトケラチノサイトおよびNIH/3T3線維芽細胞における熱ショックタンパク質HSP70の誘発は、例えば米国特許第9265743号に記載されている。 Heat shock proteins (HSPs) are molecular chaperones that prevent cell death. Organisms and cells respond to various stress conditions, such as environmental, metabolic and pathophysiological stress, by selectively upregulating HSPs. HSPs are confirmed by increased expression after heat shock (usually at a temperature 3 to 5° C. higher than room temperature for 1 hour or more). The presumption that HSPs protect cells from heat damage is supported by the following facts: 1) HSP expression occurs precisely in parallel with the development and decline of heat tolerance (heat death resistance); 2) HSP mutations or inactivation impairs the cell's ability to survive high temperatures; 3) HSP overexpression can often enhance the cell's ability to withstand high temperatures. Induction of heat shock protein HSP70 in human keratinocytes and NIH/3T3 fibroblasts by cinnamic acid derivatives, especially chlorogenic acid, has been described, for example, in US Pat. No. 9,265,743.
これらのタンパク質は、分子量に基づき、6つの主要ファミリー、すなわち、Hsp100、Hsp90、Hsp70、Hsp60、Hsp40および低分子熱ショックタンパク質(sHsp)に分類される。sHspは、12~43kDaのサブユニット分子量を有する。 タンパク質およびポリペプチドの凝集を、特に細胞タンパク質のアンフォールディングにつながるストレス状態下で、防止する能力は、多くのsHSPの最も重要な機能である。ヒトsHSPは、それらの熱誘導性発現、組織および細胞内局在、構造、基質選択性および機能に関して、様々な特徴を有する。この相違のために、ヒトsHSPは、急性のおよび種々のタイプの慢性の(疾患関連の)ストレスを防ぐ種々の能力を有する。
HSP27は、低分子熱ショックタンパク質(sHSP)に属する。HSP27は、ストレス誘導性のタンパク質凝集を防ぐATP-非依存性分子シャペロンである。Hsp27は、無傷の皮膚、主として表皮の顆粒層および有棘層において見られる。
一実施形態によれば、皮膚の熱耐性を増大するためのセイヨウノコギリソウの使用が提供される。
These proteins are classified into six major families based on molecular weight: Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and small heat shock proteins (sHsp). sHsp has a subunit molecular weight of 12-43 kDa. The ability to prevent protein and polypeptide aggregation, especially under stress conditions that lead to unfolding of cellular proteins, is the most important function of many sHSPs. Human sHSPs have different characteristics with respect to their heat-inducible expression, tissue and subcellular localization, structure, substrate selectivity and function. Because of this difference, human sHSPs have different abilities to prevent acute and different types of chronic (disease-related) stress.
HSP27 belongs to small heat shock proteins (sHSPs). HSP27 is an ATP-independent molecular chaperone that prevents stress-induced protein aggregation. Hsp27 is found in intact skin, primarily in the stratum granulosum and stratum spinosum of the epidermis.
According to one embodiment, there is provided the use of yarrow to increase heat tolerance of the skin.
皮膚の熱耐性は、熱ストレス後の他の点で損傷性または致死性の熱ストレスに対して細胞が抵抗性になる誘発性現象に関係する。Maytin E. et al. (J. Invest. Dermatol 1990;95: 635-42;J. Biol Chem. 1992; 267: 231 89-96; J. Invest Dermatol 1995; 104 [4]: 448-55, Farage MA. Textbook of Aging Skin. Springer-Verlag Berlin Heidelberg 2010)から、ヒトケラチノサイトに対する熱ストレスは、熱耐性および熱ショックタンパク質合成の増加をもたらすばかりでなく、重金属、低酸素症などの他のストレス刺激への非感受性にもつながり、驚くべきことに、UVB誘導ダメージに対する抵抗性をももたらすことを知ることができる。
一実施形態によれば、セイヨウノコギリソウはセイヨウノコギリソウフレッシュ植物圧搾汁としてまたは本発明に従った使用における化粧用組成物として使用される。
一実施形態によれば、本発明に従って使用される場合、化粧用組成物中のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の用量は、100質量%の化粧用組成物に対して0.0001~10質量%である。
好ましくは、化粧用組成物、特に皮膚および毛髪のクレンジングおよびケアのための化粧用組成物、におけるセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の用量は、0.001~5質量%、より好ましくは0.005~3質量%である。
一実施形態によれば、本発明の医薬組成物は、医薬として使用される。
本発明の医薬組成物はまた、癌予防および皮膚疾患の治療において使用されてよい。
Skin thermotolerance involves an induced phenomenon in which cells become resistant to otherwise damaging or lethal heat stress following heat stress. Maytin E. et al. (J. Invest. Dermatol 1990;95: 635-42; J. Biol Chem. 1992; 267: 231 89-96; J. Invest Dermatol 1995; 104 [4]: 448-55, Farage MA. Textbook of Aging Skin. Springer-Verlag Berlin Heidelberg 2010), heat stress on human keratinocytes not only leads to increased heat tolerance and heat shock protein synthesis, but also to other stress stimuli such as heavy metals and hypoxia. It can be seen that it also leads to insensitivity to UVB and, surprisingly, also to resistance to UVB-induced damage.
According to one embodiment, Yarrow is used as Yarrow fresh plant juice or as a cosmetic composition in use according to the invention.
According to one embodiment, when used according to the invention, the dose of Yarrow fresh plant juice concentrate in the cosmetic composition is from 0.0001 to 10% by weight relative to 100% by weight of the cosmetic composition. %.
Preferably, the dose of Yarrow fresh plant juice concentrate in cosmetic compositions, especially cosmetic compositions for skin and hair cleansing and care, is from 0.001 to 5% by weight, more preferably from 0.001 to 5% by weight. 0.005 to 3% by mass.
According to one embodiment, the pharmaceutical composition of the invention is used as a medicament.
Pharmaceutical compositions of the invention may also be used in cancer prevention and treatment of skin diseases.
アトピー性皮膚炎、日光角化症、皮膚癌前駆体、乾癬、酒さおよびバリア損傷および慢性炎症を特徴とする他の皮膚疾患などの疾患において、当該皮膚部域における熱ショックタンパク質の合成は低減し、皮膚の修復メカニズムは妨害されることが知られている。ケラチノサイトの制御されたアポトーシスにおいて、妨害が起こり、免疫防御は弱められる。これらのプロセスと並行して、マトリックスメタロプロテアーゼなどの炎症性酵素は、ますます形成される。皮膚の老化および炎症は、皮膚の修復メカニズムが妨害されかつ弱められ、かつ炎症メディエーターがますます放出されるという事実によって特徴付けられる。 In diseases such as atopic dermatitis, actinic keratoses, skin cancer precursors, psoriasis, rosacea and other skin diseases characterized by barrier damage and chronic inflammation, the synthesis of heat shock proteins in relevant skin areas is reduced. However, skin repair mechanisms are known to be disrupted. A disturbance occurs in the controlled apoptosis of keratinocytes and the immune defense is weakened. In parallel with these processes, inflammatory enzymes such as matrix metalloproteases are increasingly formed. Skin aging and inflammation are characterized by the fact that the skin's repair mechanisms are disturbed and weakened, and inflammatory mediators are increasingly released.
特に、本発明の医薬組成物は、癌療法の枠組み内で、皮膚損傷を回避および/または軽減するために使用することができる。本発明の医薬組成物のこの使用は、セイヨウノコギリソウ、特に皮膚の熱耐性を増大するセイヨウノコギリソウの成分、の発見された作用機序に基づいている。この効果は皮膚細胞における熱ショックタンパク質の発現に起因すると考えられる。この効果は、癌治療、特に皮膚癌の放射線療法の状況における薬物療法および/または放射線照射の影響から、健常な皮膚細胞を保護するために使用することができる。セイヨウノコギリソウの抗菌特性もまた、ヒト皮膚に対するこの保護効果を支える。
一実施形態によれば、セイヨウノコギリソウが本発明に従って使用されるかまたは医薬組成物が本発明に従って医薬として使用される場合、皮膚および/または毛髪への局所適用が行われる。
In particular, the pharmaceutical compositions of the invention can be used within the framework of cancer therapy to avoid and/or reduce skin damage. This use of the pharmaceutical composition of the invention is based on the discovered mechanism of action of Yarrow, in particular the components of Yarrow that increase the heat tolerance of the skin. This effect is thought to be due to the expression of heat shock proteins in skin cells. This effect can be used to protect healthy skin cells from the effects of drug therapy and/or radiation in the context of cancer treatment, particularly radiation therapy for skin cancer. Yarrow's antibacterial properties also support this protective effect on human skin.
According to one embodiment, when Yarrow is used according to the invention or the pharmaceutical composition is used as a medicament according to the invention, topical application to the skin and/or hair is carried out.
本発明の文脈において、用語「have(有する)」または「having(有している)」は、開放的な列挙を言い、明確に言及された構成要素またはステップに加えての他の構成要素またはステップを除外するものではない。本発明の文脈において、組成物が表現「have(有する)」または「having(有している)」を用いて記載される場合、組成物が指定された構成要素からなるかまたは指定された構成要素から基本的になることを、明確に含む。
本発明の文脈において、用語「consisting of(からなる)」は、網羅的な列挙を言い、明確に言及された構成要素またはステップから離れた他のいかなる構成要素またはステップをも除外する。
本発明の文脈において、用語「essentially consisting of(から基本的になる)」は、部分的に網羅的な列挙を言い、指定された構成要素に加えて、組成物の特徴を実質的に変化させないか、または組成物の特徴を実質的に変化させない量で存在するような追加の構成要素のみを含む組成物を言う。
In the context of the present invention, the term "have" or "having" refers to an open enumeration, including other components or steps in addition to the explicitly mentioned components or steps. This does not exclude steps. In the context of the present invention, if a composition is described using the expressions "have" or "having", it means that the composition consists of the specified components or has the specified configuration. It clearly includes what becomes basic from the element.
In the context of the present invention, the term "consisting of" refers to an exhaustive enumeration and excludes any other components or steps apart from the explicitly mentioned components or steps.
In the context of the present invention, the term "essentially consisting of" refers to a partially exhaustive list of components that, in addition to the specified components, do not substantially change the characteristics of the composition. or only those additional components present in amounts that do not substantially alter the characteristics of the composition.
本発明のさらなる特徴および利点は、好ましい実施例の以下の記述から生じる。 Further features and advantages of the invention result from the following description of preferred embodiments.
実施例において%で示されるすべての仕様は、明示的に別段の記載がない限り、質量%での仕様を言う。 All specifications expressed in % in the examples refer to specifications in % by weight, unless explicitly stated otherwise.
(例1)
フリーズドライによるセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の製造
独国において栽培された開花中のハーブから製造された、100mlのセイヨウノコギリソウ(Achillea millefollium)フレッシュ植物圧搾汁(Schoenenberger社)を凍結し、続いてフリーズドライする。5.3gの乾燥汁1aが、褐色-緑色固体として得られ、その組成を分析する:
Production of Achillea millefollium fresh plant press concentrate by freeze-drying 100 ml of Achillea millefollium fresh plant press (Schoenenberger), produced from a flowering herb grown in Germany, was frozen and then Freeze dry. 5.3 g of dried juice 1a are obtained as a brown-green solid and its composition is analyzed:
さらに3バッチのセイヨウノコギリソウ(Achillea millefollium)フレッシュ植物圧搾汁(Schoenenberger社)各100mlを凍結し、続いてフリーズドライする。得られた乾燥汁1b~1dを秤量し、モノ-およびジカフェオイルキナ酸の総和およびルチンについて分析する:
結果は、セイヨウノコギリソウ(Achillea millefollium)フレッシュ植物圧搾汁(Schoenenberger社)の4バッチは、平均4.7±0.4gのセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を与えた。
フリーズドライしたセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物は、平均でわずか6.6±1.0%の水、9.6±1.3%のモノカフェオイルキナ酸の総和、4.5±1.0%のジカフェオイルキナ酸の総和および0.3±0.1%のルチンを含む。
Three additional batches of Achillea millefolium fresh plant juice (Schoenenberger), 100 ml each, are frozen and subsequently freeze-dried. The resulting dried juices 1b-1d are weighed and analyzed for total mono- and dicaffeoylquinic acids and rutin:
The results showed that four batches of Achillea millefolium fresh plant juice (Schoenenberger) gave an average of 4.7±0.4 g of Achillea millefolium fresh plant juice concentrate.
Freeze-dried Yarrow fresh plant juice concentrate contains on average only 6.6±1.0% water, 9.6±1.3% total monocaffeoylquinic acid, 4.5±1. Contains 0% total dicaffeoylquinic acid and 0.3±0.1% rutin.
(例2)
噴霧乾燥によるセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の製造
1lのセイヨウノコギリソウフレッシュ植物圧搾汁(Schoenenberger社、乾燥物含有量5.3%)を150gのマルトデキストリンDE17~20と混合して噴霧乾燥する。得られるのは、75%マルトデキストリンおよび25%乾燥セイヨウノコギリソウフレッシュ植物圧搾汁からなるベージュ色の自由流動性の粉末である。噴霧乾燥濃縮物をモノ-およびジカフェオイルキナ酸の総和およびルチンについて分析する:
(Example 2)
Preparation of Yarrow Fresh Plant Juice Concentrate by Spray Drying 1 l of Yarrow Fresh Plant Juice (Schoenenberger, dry matter content 5.3%) is mixed with 150 g of maltodextrin DE 17-20 and spray dried. The result is a beige free-flowing powder consisting of 75% maltodextrin and 25% dry Yarrow fresh plant juice. The spray-dried concentrate is analyzed for total mono- and dicaffeoylquinic acids and rutin:
分析結果は、成分が噴霧乾燥の間に変化せずに残存し、分解は起こらなかったことを示す。
Analytical results show that the components remained unchanged during spray drying and no decomposition occurred.
(例3)
皮膚細胞における熱ショックタンパク質の遺伝子発現に対するセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の効果
新生児ヒト表皮ケラチノサイト(nHEK)を6ウェルのマイクロタイタープレートに、0.2×106細胞/キャビティの密度で播種し、EpiLife培地で培養する。24時間のインキュベーション期間後に、例1で得られたセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を0.005質量%の濃度で、EpiLifeに加え、24時間インキュベーションする。
(Example 3)
Effect of Yarrow Fresh Plant Juice Concentrate on Gene Expression of Heat Shock Proteins in Skin Cells Neonatal human epidermal keratinocytes (nHEK) were seeded in 6-well microtiter plates at a density of 0.2 x 10 cells/cavity. , cultured in EpiLife medium. After an incubation period of 24 hours, the Yarrow fresh plant juice concentrate obtained in Example 1 is added to the EpiLife at a concentration of 0.005% by weight and incubated for 24 hours.
mRNAの単離および精製は、Qiagen社のRNeasy(登録商標)Mini Kitを用いて行う。カラムからのmRNAの溶出は、50μlのRNaseフリー水を用いて行う。単離されたRNAの定量および純度決定は、分光光度法によって行う。純度は、吸光度比E260/E280およびE260/E230によって評価する。RNAのcDNAへの転写は、製造者の指示(RNA-to-cDNA Kit、Applied Biosystems)に従って行う。転写される量は、6ウェルあたり0.5~1μgである。転写された試料は直ちに、PCRで処理するかまたは-20℃で、実験が継続されるまで保存する。
次のステップで、qRT-PCRを行う。qRT-PCRのために、cDNAを解凍し、TaqMan(登録商標)Fast Universal PCR Master Mix (2×)(Life Technologies)と混合する。96ウェルのTaqMan(登録商標)プレート(Life Technologies、ダルムシュタット)は、所望のプライマーを個別に備えることができる。96ウェルアレイプレートの各ウェルに10μLの容量の試料をピペットで分注し、ウェルを接着フィルム(MicroAmp(登録商標))で注意深く気密に封止し、遠心分離する。遺伝子発現分析をStepOne Plus Fast Real-Time PCR装置(Applied Biosystems)で行う。加熱段階の後に、装置は自動的に表5に示すサイクルを順
次実行する。
測定値をMS Office Excelにエクスポートして評価する。相対遺伝子発現をΔΔCT法に従って算出する。算出の最初のステップにおいて、試験する遺伝子のCT値からリファレンス遺伝子(遺伝子HRPT)のCT値を減算することによって、ΔCT値を各試料について算出する。
ΔCT値標的遺伝子=CT値標的遺伝子-CT値リファレンス遺伝子(HTRP遺伝子)
標準化後に、処置試料(PS適用)のΔCT値から対照試料(非処置)のΔCT値を減算する。
ΔΔCT値標的遺伝子=ΔCT値処置-ΔCT値対照
最終ステップにおいて、刺激された試料(PS適用)と対照との間の相対発現差(相対定量値(RQ値))を算出する。相対遺伝子発現(RQ値)=2-ΔΔCT
>2.5のRQ値は、遺伝子の相対誘導とみなされる。
Measurements are exported to MS Office Excel for evaluation. Relative gene expression is calculated according to the ΔΔCT method. In the first step of calculation, the ΔCT value is calculated for each sample by subtracting the CT value of the reference gene (gene HRPT) from the CT value of the gene to be tested.
ΔCT value target gene = CT value target gene - CT value reference gene (HTRP gene)
After standardization, the ΔCT value of the control sample (untreated) is subtracted from the ΔCT value of the treated sample (PS applied).
ΔΔCT value target gene = ΔCT value treatment - ΔCT value control
In the final step, the relative expression difference (relative quantification value (RQ value)) between the stimulated sample (PS applied) and the control is calculated. Relative gene expression (RQ value) = 2 -ΔΔCT
RQ values of >2.5 are considered relative induction of the gene.
結果は、セイヨウノコギリソウフレッシュ植物圧搾汁が、非常に低い試験濃度において熱ショックタンパク質HSP27の遺伝子発現を非常に効果的に上方制御するが、HSP70には効果を及ぼさないことを示す。
The results show that Yarrow fresh plant juice very effectively upregulates the gene expression of heat shock protein HSP27, but has no effect on HSP70 at very low tested concentrations.
(例4)
皮膚細胞におけるAMPの遺伝子発現に対するセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物の効果
HaCaT細胞を、6ウェルのマイクロタイタープレートに、0.5×106細胞/ウェルの密度で播種し、EpiLife培地で培養する。
2日間のインキュベーション期間後に、例1で得られたセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を0.005質量%の濃度で、EpiLifeに加え、24時間インキュベーションする。
mRNAの単離および精製は、Qiagen社のRNeasy(登録商標)Mini Kitを用いて行う。カラムからのmRNAの溶出は、50μlのRNaseフリー水を用いて行う。単離されたRNAの定量および純度決定は、分光光度法によって行う。純度は、吸光度比E260/E280およびE260/E230によって評価する。
RNAのcDNAへの転写は、製造者の指示(RNA-to-cDNA Kit、Applied Biosystems)に従って行う。転写される量は、6ウェルあたり0.5~1μgである。転写された試料は直ちに、PCRで処理するかまたは-20℃で、実験が継続されるまで保存する。
(Example 4)
Effect of Yarrow Fresh Plant Juice Concentrate on Gene Expression of AMP in Skin Cells HaCaT cells are seeded in 6-well microtiter plates at a density of 0.5 x 10 cells/well and cultured in EpiLife medium. .
After an incubation period of 2 days, the Yarrow fresh plant juice concentrate obtained in Example 1 is added to the EpiLife at a concentration of 0.005% by weight and incubated for 24 hours.
Isolation and purification of mRNA is performed using Qiagen's RNeasy® Mini Kit. Elution of mRNA from the column is performed using 50 μl of RNase-free water. Quantification and purity determination of isolated RNA is performed spectrophotometrically. Purity is assessed by absorbance ratios E260/E280 and E260/E230.
Transcription of RNA into cDNA is performed according to the manufacturer's instructions (RNA-to-cDNA Kit, Applied Biosystems). The amount transferred is 0.5-1 μg per 6 wells. Transferred samples are immediately processed by PCR or stored at -20°C until the experiment is continued.
次のステップで、qRT-PCRを行う。qRT-PCRのために、cDNAを解凍し、TaqMan(登録商標)Fast Universal PCR Master Mix (2×)(Life Technologies)と混合する。96ウェルのTaqMan(登録商標)プレート(Life Technologies、ダルムシュタット)は、所望のプライマーを個別に備えることができる。96ウェルアレイプレートの各ウェルに10μLの容量の試料をピペットで分注し、ウェルを接着フィルム(MicroAmp(登録商標))で注意深く気密に封止し、再び1分間、遠心分離する。遺伝子発現分析をStepOne Plus Fast Real-Time PCR装置(Applied Biosystems)で行う。加熱段階の後に、装置は自動的に表8に示すサイクルを順次実行する。 In the next step, qRT-PCR is performed. For qRT-PCR, cDNA is thawed and mixed with TaqMan® Fast Universal PCR Master Mix (2×) (Life Technologies). 96-well TaqMan® plates (Life Technologies, Darmstadt) can be individually equipped with the desired primers. Pipette a volume of 10 μL of sample into each well of a 96-well array plate, carefully seal the wells hermetically with adhesive film (MicroAmp®), and centrifuge again for 1 minute. Gene expression analysis is performed on a StepOne Plus Fast Real-Time PCR machine (Applied Biosystems). After the heating step, the device automatically performs the cycles shown in Table 8 in sequence.
測定値をMS Office Excelにエクスポートして評価する。相対遺伝子発現をΔΔCT法に従って算出する。算出の最初のステップにおいて、試験する遺伝子のCT値からリファレンス遺伝子(遺伝子HRPT)のCT値を減算することによって、ΔCT値を各試料について算出する。
ΔCT値標的遺伝子=CT値標的遺伝子-CT値リファレンス遺伝子(HTRP遺伝子)
標準化後に、処置試料(PS適用)のΔCT値から対照試料(非処置)のΔCT値を減算する。
ΔΔCT値標的遺伝子=ΔCT値処置-ΔCT値対照
最終ステップにおいて、刺激された試料(PS適用)と対照との間の相対発現差(相対定量値(RQ値))を算出する。
相対遺伝子発現(RQ値)=2-ΔΔCT
>2.5のRQ値は、遺伝子の相対誘導とみなされる。
Measurements are exported to MS Office Excel for evaluation. Relative gene expression is calculated according to the ΔΔCT method. In the first step of calculation, the ΔCT value is calculated for each sample by subtracting the CT value of the reference gene (gene HRPT) from the CT value of the gene to be tested.
ΔCT value target gene = CT value target gene - CT value reference gene (HTRP gene)
After standardization, the ΔCT value of the control sample (untreated) is subtracted from the ΔCT value of the treated sample (PS applied).
ΔΔCT value target gene = ΔCT value treatment - ΔCT value control
In the final step, the relative expression difference (relative quantification value (RQ value)) between the stimulated sample (PS applied) and the control is calculated.
Relative gene expression (RQ value) = 2 -ΔΔCT
RQ values of >2.5 are considered relative induction of the gene.
結果は、セイヨウノコギリソウフレッシュ植物圧搾汁が、非常に低い試験濃度において、抗菌ペプチドβ-デフェンシン1およびS100カルシウム結合タンパク質A8の遺伝子発現を非常に効果的に上方制御することを示す。
The results show that Yarrow fresh plant juice very effectively upregulates the gene expression of the antimicrobial peptide β-defensin 1 and S100 calcium binding protein A8 at very low tested concentrations.
(例5)
処方例
1=皮膚用鎮静バーム
2=着色抗老化バーム、SPF15
3=アフターサン保湿スプレーO/W
4=ナイトクリームW/O
5=フェイシャルクレンジングゲル
6=アフターシェイブハイドロゲル
7=抗フケヘアシャンプー
8=制汗ポンプスプレー
9=スキンライトニング用デイケアフルイドO/W
10=バリア機能回復クリームO/W
11=サンプロテクションローションSPF24(UVA/UVBバランス)
処方例1~11において、以下に記載の2種の香油PFO1およびPFO2が、それぞれ、香料として使用される(DPG=ジプロピレングリコール)。
(Example 5)
Prescription example 1 = Soothing balm for skin 2 = Colored anti-aging balm, SPF15
3 = After sun moisturizing spray O/W
4=Night cream W/O
5=Facial Cleansing Gel 6=Aftershave Hydrogel 7=Anti-dandruff Hair Shampoo 8=Antiperspirant Pump Spray 9=Day Care Fluid O/W for Skin Lightening
10 = Barrier function recovery cream O/W
11 = Sun protection lotion SPF24 (UVA/UVB balance)
In formulation examples 1 to 11, the two perfume oils PFO1 and PFO2 described below are used as perfumes, respectively (DPG = dipropylene glycol).
Claims (13)
10~100質量%のセイヨウノコギリソウフレッシュ植物圧搾汁乾燥残渣、
0~10質量%の水、および
0~90質量%の担体
を含むかまたはからなる、皮膚及び/又は毛髪に局所適用するための、凍結乾燥物又は噴霧乾燥物である、セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物。 Based on the total weight of Yarrow fresh plant juice concentrate containing one or more dicaffeoylquinic acids:
10 to 100% by mass of yarrow fresh plant pressed juice dry residue,
Yarrow fresh plant press, lyophilized or spray dried, for topical application to the skin and/or hair, comprising or consisting of 0 to 10 % by weight of water and 0 to 90% by weight of carrier juice concentrate.
セイヨウノコギリソウフレッシュ植物圧搾汁を噴霧乾燥するステップ、
のステップを含むかまたはステップからなる、請求項1から5までのいずれか1項に記載のセイヨウノコギリソウフレッシュ植物圧搾汁濃縮物を製造する方法。 preparing a Yarrow fresh plant press; and spray drying the Yarrow fresh plant press;
A method for producing a yarrow fresh plant press concentrate according to any one of claims 1 to 5, comprising or consisting of the steps of:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022086275A JP7446362B2 (en) | 2017-04-28 | 2022-05-26 | Yarrow Fresh Plant Squeezed Juice Concentrate, Manufacture, and Use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2017/060175 WO2018196993A1 (en) | 2017-04-28 | 2017-04-28 | Yarrow fresh-plant pressed juice concentrate, production, and use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022086275A Division JP7446362B2 (en) | 2017-04-28 | 2022-05-26 | Yarrow Fresh Plant Squeezed Juice Concentrate, Manufacture, and Use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020518570A JP2020518570A (en) | 2020-06-25 |
JP7433908B2 true JP7433908B2 (en) | 2024-02-20 |
Family
ID=58645074
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019558768A Active JP7433908B2 (en) | 2017-04-28 | 2017-04-28 | Yarrow Fresh Plant Squeezed Juice Concentrate, Manufacture, and Use |
JP2022086275A Active JP7446362B2 (en) | 2017-04-28 | 2022-05-26 | Yarrow Fresh Plant Squeezed Juice Concentrate, Manufacture, and Use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022086275A Active JP7446362B2 (en) | 2017-04-28 | 2022-05-26 | Yarrow Fresh Plant Squeezed Juice Concentrate, Manufacture, and Use |
Country Status (6)
Country | Link |
---|---|
US (1) | US11219593B2 (en) |
EP (1) | EP3615147A1 (en) |
JP (2) | JP7433908B2 (en) |
KR (2) | KR20230040376A (en) |
CN (1) | CN110573141A (en) |
WO (1) | WO2018196993A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110218652A (en) * | 2019-05-27 | 2019-09-10 | 昆明理工大学 | A method of promoting micro algae growth and oil and fat accumulation in BG-11 culture medium |
CN112763618B (en) * | 2020-12-29 | 2022-03-01 | 四川新绿色药业科技发展有限公司 | Method for identifying characteristic spectrum of hairyvein agrimony formula particles |
CN117651544A (en) * | 2021-07-23 | 2024-03-05 | 西姆莱斯有限公司 | Synergistic effect of dicaffeoylquinic acid and tocopherol |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000505786A (en) | 1996-03-14 | 2000-05-16 | ペーター・グライトヘーア | Method for producing storable preparations from fresh plants and fresh plant preparations |
JP2001114637A (en) | 1999-10-14 | 2001-04-24 | Noevir Co Ltd | Hyaluronic acid production promoting agent and skin lotion containing the agent |
JP2002338460A (en) | 2001-05-21 | 2002-11-27 | Fancl Corp | Composition for activating skin basement membrane |
JP2012504564A (en) | 2008-10-02 | 2012-02-23 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト | Composition for treating or alleviating skin diseases or disorders associated with elevated levels of antimicrobial peptides and proteins |
JP2015508748A (en) | 2012-01-30 | 2015-03-23 | ユリエヴィッチ レシコフ,セルゲイ | Agents that induce the synthesis of heat shock proteins in human and animal cells; cosmetics to promote the repair process; cosmetics to reduce the side effects of invasive cosmetic procedures; dietary supplements; foodstuffs; side effects of invasive cosmetic procedures How to reduce |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1926166A1 (en) * | 1969-05-22 | 1970-11-26 | Walther Schoenenberger Pflanze | Vegetable and medicinal plant juice prepn |
FR2110268B1 (en) | 1970-10-07 | 1976-06-04 | Minnesota Mining & Mfg | |
GB1447988A (en) | 1973-04-03 | 1976-09-02 | Orsymonde | Pharmaceutical compositions |
GB1541463A (en) | 1975-10-11 | 1979-02-28 | Lion Dentifrice Co Ltd | Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase |
US4237253A (en) | 1977-04-21 | 1980-12-02 | L'oreal | Copolymers, their process of preparation, and cosmetic compounds containing them |
US4960764A (en) | 1987-03-06 | 1990-10-02 | Richardson-Vicks Inc. | Oil-in-water-in-silicone emulsion compositions |
DE3708451A1 (en) | 1987-03-16 | 1988-10-06 | Henkel Kgaa | ZWITTERIONIC POLYMERS AND THEIR USE IN HAIR TREATMENT AGENTS |
DE3740186A1 (en) | 1987-06-24 | 1989-01-05 | Beiersdorf Ag | DESODORATING AND ANTIMICROBIAL COMPOSITION FOR USE IN COSMETIC OR TOPICAL PREPARATIONS |
DE3929973A1 (en) | 1989-09-08 | 1991-03-14 | Henkel Kgaa | HAIR CARE |
DE3938140A1 (en) | 1989-11-16 | 1991-08-08 | Beiersdorf Ag | DESODRATING COSMETIC AGENTS |
DE4204321A1 (en) | 1992-02-13 | 1993-08-19 | Beiersdorf Ag | METHOD FOR THE INSULATION AND CLEANING OF FATS AND HYDROXYFASTAEURES AND USES OF HYDROXYFAST ATTACHMENTS AND PREPARATIONS THEREOF CONTAINED |
DE4229707A1 (en) | 1992-09-05 | 1994-03-10 | Beiersdorf Ag | Germicide drug combinations |
DE4229737C2 (en) | 1992-09-05 | 1996-04-25 | Beiersdorf Ag | Deodorizing cosmetic products containing fatty acids |
DE4237081C2 (en) | 1992-11-03 | 1996-05-09 | Beiersdorf Ag | Use of di- or triglycerol esters as Deowirkstoffe |
DE4309372C2 (en) | 1993-03-23 | 1997-08-21 | Beiersdorf Ag | Cosmetic deodorants containing mixtures of wool wax acids or wool wax acid components and fatty acid partial glycerides of unbranched fatty acids |
DE4324219C2 (en) | 1993-07-20 | 1995-08-10 | Beiersdorf Ag | Deodorant active ingredient combinations based on alpha, omega-alkane dicarboxylic acids and wool wax acids |
DE4333238A1 (en) | 1993-09-30 | 1995-04-06 | Basf Ag | Polyesters and polyamides containing pyrrolidone groups |
DE4411664A1 (en) | 1994-04-05 | 1995-10-12 | Beiersdorf Ag | Novel deodorant and antimicrobial compositions for use in cosmetic or topical preparations |
FR2720937B1 (en) | 1994-06-08 | 1997-03-28 | Oreal | Cosmetic or dermatological composition in the form of an aqueous and stable dispersion of cubic gel particles based on phytantriol and containing a fatty chain surfactant as a dispersing and stabilizing agent. |
DE4423410C2 (en) | 1994-07-04 | 1996-07-18 | Beiersdorf Ag | Deodorant active ingredient combinations based on alpha, omega-alkanedicarboxylic acids and monocarboxylic acid esters of oligoglycerides |
DE4429467C2 (en) | 1994-08-19 | 1997-10-02 | Beiersdorf Ag | Deodorizing cosmetic products |
WO1996028139A1 (en) | 1995-03-14 | 1996-09-19 | The Procter & Gamble Company | Dispersed smectite clay as oil in water stabilizer for skin cleansing liquid composition |
DE19516705C2 (en) | 1995-05-06 | 1997-10-02 | Beiersdorf Ag | Substances effective against bacteria, mycota and viruses |
DE19541967A1 (en) | 1995-11-10 | 1997-05-15 | Beiersdorf Ag | Combination, useful as deodorant for personal care |
DE19543695A1 (en) | 1995-11-23 | 1997-05-28 | Beiersdorf Ag | Compositions based on alpha-hydroxyalkanoic acids and squalene, effective against bacteria, Mycota and viruses |
DE19543696A1 (en) | 1995-11-23 | 1997-05-28 | Beiersdorf Ag | Against bacteria, Mycota and viruses effective combinations of active ingredients based on partial glycerides and dialkyl-substituted acetic acids |
US20020165168A1 (en) | 1995-12-16 | 2002-11-07 | Joachim Bunger | Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances |
DE19602110A1 (en) | 1996-01-22 | 1997-07-24 | Beiersdorf Ag | Compositions based on squalene and sphingolipids which are effective against bacteria, parasites, protozoa, mycota and viruses |
DE19602108A1 (en) | 1996-01-22 | 1997-07-24 | Beiersdorf Ag | Substances effective against bacteria, parasites, protozoa, mycota and viruses |
DE19602111A1 (en) | 1996-01-22 | 1997-07-24 | Beiersdorf Ag | New active agent combinations useful in cosmetic and dermatological compositions |
IL126987A (en) | 1996-05-10 | 2001-09-13 | Nino Shikhashvili | Green ointment for burn and wound treatment |
DE19631003A1 (en) | 1996-08-01 | 1998-02-05 | Beiersdorf Ag | Against bacteria, Mycota and viruses effective drug combinations based on partial glycerides and dialkyl-substituted acetic acids |
DE19631004A1 (en) | 1996-08-01 | 1998-02-05 | Beiersdorf Ag | Deodorizing combinations of active substances based on woollysilicic acids, partial glycerides and aryl compounds |
DE19634019A1 (en) | 1996-08-23 | 1998-02-26 | Beiersdorf Ag | Antimicrobial, antiviral, antiparasitic and antiprotozoal agents |
JPH11199500A (en) | 1998-01-07 | 1999-07-27 | Nissin Food Prod Co Ltd | Atopic dermatitis therapeutic agent |
JPH11246347A (en) * | 1998-03-05 | 1999-09-14 | Shiseido Co Ltd | Preparation for external use for skin bleaching |
DE19817177A1 (en) | 1998-04-17 | 1999-10-21 | Lohmann Rudolf Lomapharm | Preparation of plant derived polysaccharides with immune system stimulating activity |
DE29924656U1 (en) | 1999-03-25 | 2004-08-19 | Symrise Gmbh & Co. Kg | Sunscreen composition for topical application on human skin to protect skin against radiation damage |
US5993789A (en) | 1999-03-25 | 1999-11-30 | The C.P. Hall Company | Photostable sunscreen compositions containing dibenzoylmethane derivative, E.G., parsol® 1789, and diesters or polyesters of naphthalene dicarboxylic acid photostabilizers and enhancers of the sun protection factor (SPF) |
JP2002060317A (en) | 2000-10-03 | 2002-02-26 | Noevir Co Ltd | Skin care preparation |
JP2002121126A (en) | 2000-10-13 | 2002-04-23 | Noevir Co Ltd | Skin care preparation |
US20040096418A1 (en) * | 2001-02-16 | 2004-05-20 | Thomas Gafner | Cosmetically effective composition containing malva sylvestris and mentha piperita extracts |
JP2004168705A (en) | 2002-11-20 | 2004-06-17 | Pola Chem Ind Inc | Preparation for external use for ameliorating skin condition |
JP4262494B2 (en) | 2003-02-19 | 2009-05-13 | ポーラ化成工業株式会社 | Melanocyte dendrite elongation inhibitor |
US9987217B2 (en) | 2004-06-18 | 2018-06-05 | Symrise Ag | Blackberry extract |
JP2008517037A (en) | 2004-10-22 | 2008-05-22 | シムライズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツト・ゲゼルシヤフト | Synergistic mixture comprising 1,2-hexanediol and 1,2-octanediol and further a preservative |
EP2597974A1 (en) * | 2010-07-29 | 2013-06-05 | The University Of Sydney | Vegetable and fruit juice powder |
JP2013087058A (en) | 2011-10-13 | 2013-05-13 | Ichimaru Pharcos Co Ltd | Aquaporin production enhancing preparation |
KR20150061818A (en) * | 2013-11-28 | 2015-06-05 | 강원도 | Method of preparing water-soluble wild edible powder |
CN105147757A (en) * | 2014-05-05 | 2015-12-16 | 阿克塞斯商业集团国际有限责任公司 | Compositions including a botanical extract and methods of using the same in skin whitening and skin lightening applications |
EP2952103B1 (en) | 2014-06-05 | 2019-05-08 | Symrise AG | Component mixtures |
CN105687059A (en) * | 2016-04-05 | 2016-06-22 | 余云丰 | Cosmetic composition for relieving senescence, as well as preparation method and application thereof |
CN106333887A (en) * | 2016-08-30 | 2017-01-18 | 陈燕兰 | Plant extract having acne removal function and preparation method and application thereof |
-
2017
- 2017-04-28 EP EP17720478.1A patent/EP3615147A1/en active Pending
- 2017-04-28 US US16/608,907 patent/US11219593B2/en active Active
- 2017-04-28 JP JP2019558768A patent/JP7433908B2/en active Active
- 2017-04-28 WO PCT/EP2017/060175 patent/WO2018196993A1/en active Application Filing
- 2017-04-28 CN CN201780090111.8A patent/CN110573141A/en active Pending
- 2017-04-28 KR KR1020237008194A patent/KR20230040376A/en not_active Application Discontinuation
- 2017-04-28 KR KR1020197034290A patent/KR20200002947A/en not_active IP Right Cessation
-
2022
- 2022-05-26 JP JP2022086275A patent/JP7446362B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000505786A (en) | 1996-03-14 | 2000-05-16 | ペーター・グライトヘーア | Method for producing storable preparations from fresh plants and fresh plant preparations |
JP2001114637A (en) | 1999-10-14 | 2001-04-24 | Noevir Co Ltd | Hyaluronic acid production promoting agent and skin lotion containing the agent |
JP2002338460A (en) | 2001-05-21 | 2002-11-27 | Fancl Corp | Composition for activating skin basement membrane |
JP2012504564A (en) | 2008-10-02 | 2012-02-23 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト | Composition for treating or alleviating skin diseases or disorders associated with elevated levels of antimicrobial peptides and proteins |
JP2015508748A (en) | 2012-01-30 | 2015-03-23 | ユリエヴィッチ レシコフ,セルゲイ | Agents that induce the synthesis of heat shock proteins in human and animal cells; cosmetics to promote the repair process; cosmetics to reduce the side effects of invasive cosmetic procedures; dietary supplements; foodstuffs; side effects of invasive cosmetic procedures How to reduce |
Also Published As
Publication number | Publication date |
---|---|
US20200188290A1 (en) | 2020-06-18 |
US11219593B2 (en) | 2022-01-11 |
JP7446362B2 (en) | 2024-03-08 |
KR20200002947A (en) | 2020-01-08 |
EP3615147A1 (en) | 2020-03-04 |
CN110573141A (en) | 2019-12-13 |
WO2018196993A1 (en) | 2018-11-01 |
JP2022118016A (en) | 2022-08-12 |
JP2020518570A (en) | 2020-06-25 |
KR20230040376A (en) | 2023-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7446362B2 (en) | Yarrow Fresh Plant Squeezed Juice Concentrate, Manufacture, and Use | |
JP6081551B2 (en) | Composition comprising sorbitan monocaprylate and antibacterial active substance | |
JP6505905B2 (en) | Cosmetics of catechin fatty acid derivatives | |
JP7039121B2 (en) | Antiseptic antibacterial agent for cosmetics | |
CN107412031B (en) | Skin external composition containing hesperetin | |
JP2004339142A (en) | Skin cosmetic | |
KR102412958B1 (en) | Antibacterial or conservative composition containing polyglycerine-3 | |
JP2005179308A (en) | Antiallergy composition | |
JP2013234140A (en) | Trichogenous agent | |
BR112013027489B1 (en) | cosmetic use of e-polylysine (epsilon-polylysine) | |
JP2004075646A (en) | Cosmetic | |
JP6861134B2 (en) | Hyaluronic acid production promoter and hyaluronic acid production promoter food | |
JP4472428B2 (en) | Antibacterial agent | |
EP3648735B1 (en) | Novel use | |
WO2011061144A2 (en) | The present invention relates to the use of beta-(1, 3)- beta-(1, 4) glucan with an average molecular weight of from 5.000 to 150.000 da for the increase of synthesis of collagen | |
JP6902392B2 (en) | Carbonylation inhibitor | |
KR100829717B1 (en) | Astringent Cosmetic Composition Comprising the Extract from the Fruit of Poncirus trifoliata as Active Ingredient | |
KR101695549B1 (en) | A composition for skin regeneration comprising Juglone | |
CN113194910B (en) | Cosmetic composition for skin regeneration | |
TWI803713B (en) | Use of a compound as an active ingredient in the preparation of a cosmetic composition for skin regeneration | |
JP6947484B2 (en) | Innate immunity activator | |
JP6964393B2 (en) | Carbonylation inhibitor and saccharification inhibitor | |
JP2021168632A (en) | Age production suppressor | |
WO2019096634A1 (en) | Topical compositions | |
JP2019026564A (en) | Sugar-derived carbonylated protein production inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200414 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210401 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210823 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220526 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220526 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220603 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220606 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220617 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231206 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20231206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7433908 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |